{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "961214c8",
   "metadata": {},
   "source": [
    "predÏÖã Î∏åÎûúÎìúÎÑ§ÏûÑ Î≥ÄÌôò (Ï†ïÎãµÏÖãÏùÄ Ïù¥ÎØ∏ Î≥ÄÌôòÌï¥ÏÑú Ïû¨ÏÇ¨Ïö©)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "60f14071",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import re\n",
    "\n",
    "# üîπ ÏïàÏ†ÑÌïú CSV Î°úÎìú Ìï®Ïàò (UTF-8 ‚Üí CP949 ÏàúÏ∞® ÏãúÎèÑ)\n",
    "def safe_read_csv(path):\n",
    "    try:\n",
    "        return pd.read_csv(path, encoding='utf-8')\n",
    "    except UnicodeDecodeError:\n",
    "        return pd.read_csv(path, encoding='cp949')\n",
    "\n",
    "# 1Ô∏è‚É£ CSV ÌååÏùº Î∂àÎü¨Ïò§Í∏∞\n",
    "df_gold = safe_read_csv('t0.csv')   # Ï†ïÎãµÏÖã\n",
    "df_pred = safe_read_csv('t1.csv')   # ÏòàÏ∏°ÏÖã"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "b44e85c4",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>title</th>\n",
       "      <th>drug</th>\n",
       "      <th>generic_name</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>conditionally reprogrammed colorectal cancer c...</td>\n",
       "      <td>cetuximab; palbociclib; sorafenib; trametinib</td>\n",
       "      <td>cetuximab;palbociclib;sorafenib;trametinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>combining mek and src inhibitors for treatment...</td>\n",
       "      <td>dasatinib; trametinib</td>\n",
       "      <td>dasatinib;trametinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>sensitivity of kras-mutant colorectal cancers ...</td>\n",
       "      <td>palbociclib; trametinib</td>\n",
       "      <td>palbociclib;trametinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>targeting ras mutant colorectal cancer with du...</td>\n",
       "      <td>palbociclib; trametinib</td>\n",
       "      <td>palbociclib;trametinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>mcl-1 inhibition overcomes intrinsic and acqui...</td>\n",
       "      <td>regorafenib; s63845</td>\n",
       "      <td>regorafenib;s63845</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                               title  \\\n",
       "0  conditionally reprogrammed colorectal cancer c...   \n",
       "1  combining mek and src inhibitors for treatment...   \n",
       "2  sensitivity of kras-mutant colorectal cancers ...   \n",
       "3  targeting ras mutant colorectal cancer with du...   \n",
       "4  mcl-1 inhibition overcomes intrinsic and acqui...   \n",
       "\n",
       "                                            drug  \\\n",
       "0  cetuximab; palbociclib; sorafenib; trametinib   \n",
       "1                          dasatinib; trametinib   \n",
       "2                        palbociclib; trametinib   \n",
       "3                        palbociclib; trametinib   \n",
       "4                            regorafenib; s63845   \n",
       "\n",
       "                                 generic_name  \n",
       "0  cetuximab;palbociclib;sorafenib;trametinib  \n",
       "1                        dasatinib;trametinib  \n",
       "2                      palbociclib;trametinib  \n",
       "3                      palbociclib;trametinib  \n",
       "4                          regorafenib;s63845  "
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "t0.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "3c784477",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>drug</th>\n",
       "      <th>title</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>PALLADIUM;LEE</td>\n",
       "      <td>CDK4/6 Inhibitors Impede Chemoresistance and I...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>-</td>\n",
       "      <td>Conditionally reprogrammed colorectal cancer c...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>TRAMETINIB;NAVITOCLAX;NAVTEMADLIN</td>\n",
       "      <td>KRT-232 and navitoclax enhance trametinib‚Äôs an...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>LIFIRAFENIB;DABRAFENIB;CETUXIMAB</td>\n",
       "      <td>BGB-283, a Novel RAF Kinase and EGFR Inhibitor...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>LAPATINIB;TRASTUZUMAB;PERTUZUMAB;TRASTUZUMAB E...</td>\n",
       "      <td>Acquired resistance to trastuzumab/pertuzumab ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                drug  \\\n",
       "0                                      PALLADIUM;LEE   \n",
       "1                                                  -   \n",
       "2                  TRAMETINIB;NAVITOCLAX;NAVTEMADLIN   \n",
       "3                   LIFIRAFENIB;DABRAFENIB;CETUXIMAB   \n",
       "4  LAPATINIB;TRASTUZUMAB;PERTUZUMAB;TRASTUZUMAB E...   \n",
       "\n",
       "                                               title  \n",
       "0  CDK4/6 Inhibitors Impede Chemoresistance and I...  \n",
       "1  Conditionally reprogrammed colorectal cancer c...  \n",
       "2  KRT-232 and navitoclax enhance trametinib‚Äôs an...  \n",
       "3  BGB-283, a Novel RAF Kinase and EGFR Inhibitor...  \n",
       "4  Acquired resistance to trastuzumab/pertuzumab ...  "
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "t1.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "96f088e5",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>title</th>\n",
       "      <th>drug</th>\n",
       "      <th>generic_name</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>conditionally reprogrammed colorectal cancer c...</td>\n",
       "      <td>cetuximab; palbociclib; sorafenib; trametinib</td>\n",
       "      <td>cetuximab;palbociclib;sorafenib;trametinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>combining mek and src inhibitors for treatment...</td>\n",
       "      <td>dasatinib; trametinib</td>\n",
       "      <td>dasatinib;trametinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>sensitivity of kras-mutant colorectal cancers ...</td>\n",
       "      <td>palbociclib; trametinib</td>\n",
       "      <td>palbociclib;trametinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>targeting ras mutant colorectal cancer with du...</td>\n",
       "      <td>palbociclib; trametinib</td>\n",
       "      <td>palbociclib;trametinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>mcl-1 inhibition overcomes intrinsic and acqui...</td>\n",
       "      <td>regorafenib; s63845</td>\n",
       "      <td>regorafenib;s63845</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                               title  \\\n",
       "0  conditionally reprogrammed colorectal cancer c...   \n",
       "1  combining mek and src inhibitors for treatment...   \n",
       "2  sensitivity of kras-mutant colorectal cancers ...   \n",
       "3  targeting ras mutant colorectal cancer with du...   \n",
       "4  mcl-1 inhibition overcomes intrinsic and acqui...   \n",
       "\n",
       "                                            drug  \\\n",
       "0  cetuximab; palbociclib; sorafenib; trametinib   \n",
       "1                          dasatinib; trametinib   \n",
       "2                        palbociclib; trametinib   \n",
       "3                        palbociclib; trametinib   \n",
       "4                            regorafenib; s63845   \n",
       "\n",
       "                                 generic_name  \n",
       "0  cetuximab;palbociclib;sorafenib;trametinib  \n",
       "1                        dasatinib;trametinib  \n",
       "2                      palbociclib;trametinib  \n",
       "3                      palbociclib;trametinib  \n",
       "4                          regorafenib;s63845  "
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_gold.head()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "f60ba22e",
   "metadata": {},
   "outputs": [],
   "source": [
    "t0 = pd.read_csv('t0.csv', encoding=\"cp949\")  # ÎòêÎäî encoding=\"euc-kr\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "id": "612de0d6",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>title</th>\n",
       "      <th>drug</th>\n",
       "      <th>generic_name</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>conditionally reprogrammed colorectal cancer c...</td>\n",
       "      <td>cetuximab; palbociclib; sorafenib; trametinib</td>\n",
       "      <td>cetuximab;palbociclib;sorafenib;trametinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>combining mek and src inhibitors for treatment...</td>\n",
       "      <td>dasatinib; trametinib</td>\n",
       "      <td>dasatinib;trametinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>sensitivity of kras-mutant colorectal cancers ...</td>\n",
       "      <td>palbociclib; trametinib</td>\n",
       "      <td>palbociclib;trametinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>targeting ras mutant colorectal cancer with du...</td>\n",
       "      <td>palbociclib; trametinib</td>\n",
       "      <td>palbociclib;trametinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>mcl-1 inhibition overcomes intrinsic and acqui...</td>\n",
       "      <td>regorafenib; s63845</td>\n",
       "      <td>regorafenib;s63845</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>158</th>\n",
       "      <td>lkb1 regulates jnk-dependent stress signaling ...</td>\n",
       "      <td>amg176; sotorasib; trametinib</td>\n",
       "      <td>tapotoclax;sotorasib;trametinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>159</th>\n",
       "      <td>antitumor efficacy of xpo1 inhibitor selinexor...</td>\n",
       "      <td>crizotinib; erlotinib; selinexor; trametinib</td>\n",
       "      <td>crizotinib;erlotinib;selinexor;trametinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>160</th>\n",
       "      <td>signature-driven repurposing of midostaurin fo...</td>\n",
       "      <td>midostaurin; trametinib</td>\n",
       "      <td>midostaurin;trametinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>161</th>\n",
       "      <td>costunolide is a dual inhibitor of mek1 and ak...</td>\n",
       "      <td>costunolide; osimertinib</td>\n",
       "      <td>costunolide;osimertinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>162</th>\n",
       "      <td>krt-232 and navitoclax enhance trametinib?ÏÖ≤ an...</td>\n",
       "      <td>krt-232; krt232; navitoclax; trametinib</td>\n",
       "      <td>navtemadlin;navitoclax;trametinib</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>163 rows √ó 3 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                 title  \\\n",
       "0    conditionally reprogrammed colorectal cancer c...   \n",
       "1    combining mek and src inhibitors for treatment...   \n",
       "2    sensitivity of kras-mutant colorectal cancers ...   \n",
       "3    targeting ras mutant colorectal cancer with du...   \n",
       "4    mcl-1 inhibition overcomes intrinsic and acqui...   \n",
       "..                                                 ...   \n",
       "158  lkb1 regulates jnk-dependent stress signaling ...   \n",
       "159  antitumor efficacy of xpo1 inhibitor selinexor...   \n",
       "160  signature-driven repurposing of midostaurin fo...   \n",
       "161  costunolide is a dual inhibitor of mek1 and ak...   \n",
       "162  krt-232 and navitoclax enhance trametinib?ÏÖ≤ an...   \n",
       "\n",
       "                                              drug  \\\n",
       "0    cetuximab; palbociclib; sorafenib; trametinib   \n",
       "1                            dasatinib; trametinib   \n",
       "2                          palbociclib; trametinib   \n",
       "3                          palbociclib; trametinib   \n",
       "4                              regorafenib; s63845   \n",
       "..                                             ...   \n",
       "158                  amg176; sotorasib; trametinib   \n",
       "159   crizotinib; erlotinib; selinexor; trametinib   \n",
       "160                        midostaurin; trametinib   \n",
       "161                       costunolide; osimertinib   \n",
       "162        krt-232; krt232; navitoclax; trametinib   \n",
       "\n",
       "                                   generic_name  \n",
       "0    cetuximab;palbociclib;sorafenib;trametinib  \n",
       "1                          dasatinib;trametinib  \n",
       "2                        palbociclib;trametinib  \n",
       "3                        palbociclib;trametinib  \n",
       "4                            regorafenib;s63845  \n",
       "..                                          ...  \n",
       "158             tapotoclax;sotorasib;trametinib  \n",
       "159   crizotinib;erlotinib;selinexor;trametinib  \n",
       "160                      midostaurin;trametinib  \n",
       "161                     costunolide;osimertinib  \n",
       "162           navtemadlin;navitoclax;trametinib  \n",
       "\n",
       "[163 rows x 3 columns]"
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "t0"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "id": "6f42ffaf",
   "metadata": {},
   "outputs": [],
   "source": [
    "t1 = pd.read_csv('t1.csv', encoding=\"utf-8\")  # ÎòêÎäî encoding=\"euc-kr\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "id": "a66fbdab",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "from drugname_standardizer import DrugStandardizer\n",
    "\n",
    "# CSV Î∂àÎü¨Ïò§Í∏∞\n",
    "file_path = \"t1.csv\"  # Ïã§Ï†ú ÌååÏùº Í≤ΩÎ°ú\n",
    "t1 = pd.read_csv(file_path)\n",
    "\n",
    "# DrugStandardizer Í∞ùÏ≤¥ ÏÉùÏÑ±\n",
    "ds = DrugStandardizer()\n",
    "\n",
    "# drug Ïª¨Îüº ÎÇ¥ ';' Íµ¨Î∂Ñ ÏïΩÎ¨º Ï†úÎÑàÎ¶≠ÏúºÎ°ú Î≥ÄÌôò\n",
    "t1[\"drug\"] = t1[\"drug\"].apply(lambda x: \";\".join([ds.standardize_name(d.strip()) \n",
    "                                                  for d in str(x).split(\";\")]) \n",
    "                              if pd.notna(x) else \"\")\n",
    "\n",
    "# Í∏∞Ï°¥ ÌååÏùºÏóê ÎçÆÏñ¥Ïì∞Í∏∞\n",
    "t1.to_csv(file_path, index=False)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "id": "e033fb93",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>drug</th>\n",
       "      <th>title</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>PALLADIUM;LEE</td>\n",
       "      <td>CDK4/6 Inhibitors Impede Chemoresistance and I...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>-</td>\n",
       "      <td>Conditionally reprogrammed colorectal cancer c...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>TRAMETINIB;NAVITOCLAX;NAVTEMADLIN</td>\n",
       "      <td>KRT-232 and navitoclax enhance trametinib‚Äôs an...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>LIFIRAFENIB;DABRAFENIB;CETUXIMAB</td>\n",
       "      <td>BGB-283, a Novel RAF Kinase and EGFR Inhibitor...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>LAPATINIB;TRASTUZUMAB;PERTUZUMAB;TRASTUZUMAB E...</td>\n",
       "      <td>Acquired resistance to trastuzumab/pertuzumab ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                drug  \\\n",
       "0                                      PALLADIUM;LEE   \n",
       "1                                                  -   \n",
       "2                  TRAMETINIB;NAVITOCLAX;NAVTEMADLIN   \n",
       "3                   LIFIRAFENIB;DABRAFENIB;CETUXIMAB   \n",
       "4  LAPATINIB;TRASTUZUMAB;PERTUZUMAB;TRASTUZUMAB E...   \n",
       "\n",
       "                                               title  \n",
       "0  CDK4/6 Inhibitors Impede Chemoresistance and I...  \n",
       "1  Conditionally reprogrammed colorectal cancer c...  \n",
       "2  KRT-232 and navitoclax enhance trametinib‚Äôs an...  \n",
       "3  BGB-283, a Novel RAF Kinase and EGFR Inhibitor...  \n",
       "4  Acquired resistance to trastuzumab/pertuzumab ...  "
      ]
     },
     "execution_count": 26,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "t1.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "5f593a2e",
   "metadata": {},
   "source": [
    "Îëê Í∞ú csvÎ∂àÎü¨ÏôÄÏÑú Ï†ÑÏ≤¥ Ïª¨Îüº Ï†ÑÏ≤òÎ¶¨"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "id": "323c8e29",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import re\n",
    "\n",
    "# üîπ ÏïàÏ†ÑÌïú CSV Î°úÎìú Ìï®Ïàò (UTF-8 ‚Üí CP949 ÏàúÏ∞® ÏãúÎèÑ)\n",
    "def safe_read_csv(path):\n",
    "    try:\n",
    "        return pd.read_csv(path, encoding='utf-8')\n",
    "    except UnicodeDecodeError:\n",
    "        return pd.read_csv(path, encoding='cp949')\n",
    "\n",
    "# 1Ô∏è‚É£ CSV ÌååÏùº Î∂àÎü¨Ïò§Í∏∞\n",
    "df_gold = safe_read_csv('t0.csv')   # Ï†ïÎãµÏÖã\n",
    "df_pred = safe_read_csv('t1.csv')   # ÏòàÏ∏°ÏÖã\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "id": "cbed63b9",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>drug</th>\n",
       "      <th>title</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>PALLADIUM;LEE</td>\n",
       "      <td>CDK4/6 Inhibitors Impede Chemoresistance and I...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>-</td>\n",
       "      <td>Conditionally reprogrammed colorectal cancer c...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>TRAMETINIB;NAVITOCLAX;NAVTEMADLIN</td>\n",
       "      <td>KRT-232 and navitoclax enhance trametinib‚Äôs an...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>LIFIRAFENIB;DABRAFENIB;CETUXIMAB</td>\n",
       "      <td>BGB-283, a Novel RAF Kinase and EGFR Inhibitor...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>LAPATINIB;TRASTUZUMAB;PERTUZUMAB;TRASTUZUMAB E...</td>\n",
       "      <td>Acquired resistance to trastuzumab/pertuzumab ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                drug  \\\n",
       "0                                      PALLADIUM;LEE   \n",
       "1                                                  -   \n",
       "2                  TRAMETINIB;NAVITOCLAX;NAVTEMADLIN   \n",
       "3                   LIFIRAFENIB;DABRAFENIB;CETUXIMAB   \n",
       "4  LAPATINIB;TRASTUZUMAB;PERTUZUMAB;TRASTUZUMAB E...   \n",
       "\n",
       "                                               title  \n",
       "0  CDK4/6 Inhibitors Impede Chemoresistance and I...  \n",
       "1  Conditionally reprogrammed colorectal cancer c...  \n",
       "2  KRT-232 and navitoclax enhance trametinib‚Äôs an...  \n",
       "3  BGB-283, a Novel RAF Kinase and EGFR Inhibitor...  \n",
       "4  Acquired resistance to trastuzumab/pertuzumab ...  "
      ]
     },
     "execution_count": 28,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "t1.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "id": "1143ae98",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>title</th>\n",
       "      <th>drug</th>\n",
       "      <th>generic_name</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>conditionally reprogrammed colorectal cancer c...</td>\n",
       "      <td>cetuximab; palbociclib; sorafenib; trametinib</td>\n",
       "      <td>cetuximab;palbociclib;sorafenib;trametinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>combining mek and src inhibitors for treatment...</td>\n",
       "      <td>dasatinib; trametinib</td>\n",
       "      <td>dasatinib;trametinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>sensitivity of kras-mutant colorectal cancers ...</td>\n",
       "      <td>palbociclib; trametinib</td>\n",
       "      <td>palbociclib;trametinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>targeting ras mutant colorectal cancer with du...</td>\n",
       "      <td>palbociclib; trametinib</td>\n",
       "      <td>palbociclib;trametinib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>mcl-1 inhibition overcomes intrinsic and acqui...</td>\n",
       "      <td>regorafenib; s63845</td>\n",
       "      <td>regorafenib;s63845</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                               title  \\\n",
       "0  conditionally reprogrammed colorectal cancer c...   \n",
       "1  combining mek and src inhibitors for treatment...   \n",
       "2  sensitivity of kras-mutant colorectal cancers ...   \n",
       "3  targeting ras mutant colorectal cancer with du...   \n",
       "4  mcl-1 inhibition overcomes intrinsic and acqui...   \n",
       "\n",
       "                                            drug  \\\n",
       "0  cetuximab; palbociclib; sorafenib; trametinib   \n",
       "1                          dasatinib; trametinib   \n",
       "2                        palbociclib; trametinib   \n",
       "3                        palbociclib; trametinib   \n",
       "4                            regorafenib; s63845   \n",
       "\n",
       "                                 generic_name  \n",
       "0  cetuximab;palbociclib;sorafenib;trametinib  \n",
       "1                        dasatinib;trametinib  \n",
       "2                      palbociclib;trametinib  \n",
       "3                      palbociclib;trametinib  \n",
       "4                          regorafenib;s63845  "
      ]
     },
     "execution_count": 29,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "t0.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "f08b578a",
   "metadata": {},
   "source": [
    "title Ï†ÑÏ≤òÎ¶¨"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "id": "63a4a89d",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "0    conditionallyreprogrammedcolorectalcancercells...\n",
      "1    combiningmekandsrcinhibitorsfortreatmentofcolo...\n",
      "2    sensitivityofkrasmutantcolorectalcancerstocomb...\n",
      "3    targetingrasmutantcolorectalcancerwithdualinhi...\n",
      "4    mcl1inhibitionovercomesintrinsicandacquiredreg...\n",
      "Name: title, dtype: object\n",
      "0    cdk4/6inhibitorsimpedechemoresistanceandinhibi...\n",
      "1    conditionallyreprogrammedcolorectalcancercells...\n",
      "2    krt232andnavitoclaxenhancetrametinib‚Äôsanticanc...\n",
      "3    bgb283anovelrafkinaseandegfrinhibitordisplaysp...\n",
      "4    acquiredresistancetotrastuzumab/pertuzumaborto...\n",
      "Name: title, dtype: object\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import re\n",
    "\n",
    "# CSV Î∂àÎü¨Ïò§Í∏∞\n",
    "df1 = pd.read_csv(\"t0.csv\", encoding=\"cp949\")  # ÎòêÎäî encoding=\"euc-kr\"\n",
    "df2 = pd.read_csv(\"t1.csv\")\n",
    "\n",
    "# Î¨∏ÏûêÏó¥ Ï†ïÍ∑úÌôî Ìï®Ïàò\n",
    "def normalize_text(text):\n",
    "    if pd.isna(text):\n",
    "        return \"\"\n",
    "    text = text.lower()                          # ÏÜåÎ¨∏Ïûê Î≥ÄÌôò\n",
    "    text = re.sub(r\"[\\s,;:\\-\\'\\\"()]\", \"\", text) # Í≥µÎ∞±, ÌäπÏàòÎ¨∏Ïûê Ï†úÍ±∞\n",
    "    return text.strip()\n",
    "\n",
    "# Í∏∞Ï°¥ title Ïª¨Îüº ÎçÆÏñ¥Ïì∞Í∏∞\n",
    "df1[\"title\"] = df1[\"title\"].apply(normalize_text)\n",
    "df2[\"title\"] = df2[\"title\"].apply(normalize_text)\n",
    "\n",
    "# ÌôïÏù∏\n",
    "print(df1[\"title\"].head())\n",
    "print(df2[\"title\"].head())\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "80d312a9",
   "metadata": {},
   "source": [
    "Ïû¨ÌòÑÏú® Í≥ÑÏÇ∞"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "id": "765ce873",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "=== Title ÏôÑÏ†Ñ Îß§Ïπ≠ Í≤∞Í≥º ===\n",
      "Empty DataFrame\n",
      "Columns: [title, drug_t0, drug_t1]\n",
      "Index: []\n",
      "\n",
      "Drug Recall (Exact Title Match Í∏∞Ï§Ä): 0.0000\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "\n",
    "# CSV Î∂àÎü¨Ïò§Í∏∞ (Ïù¥ÎØ∏ title Ï†ÑÏ≤òÎ¶¨ ÏôÑÎ£å)\n",
    "# t0: Ï†ïÎãµÏÖã, t1: ÏòàÏ∏°ÏÖã\n",
    "# t0 = pd.read_csv(\"t0.csv\")\n",
    "# t1 = pd.read_csv(\"t1.csv\")\n",
    "\n",
    "# 1Ô∏è‚É£ title Í∏∞Ï§Ä ÏôÑÏ†Ñ Îß§Ïπ≠\n",
    "matched_df = pd.merge(t0, t1, on=\"title\", how=\"inner\", suffixes=(\"_t0\", \"_t1\"))\n",
    "\n",
    "# Îß§Ïπ≠ Í≤∞Í≥º ÌôïÏù∏\n",
    "print(\"=== Title ÏôÑÏ†Ñ Îß§Ïπ≠ Í≤∞Í≥º ===\")\n",
    "print(matched_df[[\"title\", \"drug_t0\", \"drug_t1\"]].head())\n",
    "\n",
    "# 2Ô∏è‚É£ drug Ïû¨ÌòÑÏú® Í≥ÑÏÇ∞ (t0 Í∏∞Ï§Ä)\n",
    "matched_drugs = matched_df[\"drug_t0\"] == matched_df[\"drug_t1\"]\n",
    "recall = matched_drugs.sum() / t0[\"drug\"].nunique()\n",
    "\n",
    "print(f\"\\nDrug Recall (Exact Title Match Í∏∞Ï§Ä): {recall:.4f}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "id": "9d6f7d44",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "=== Title Ïú†ÏÇ¨ÎèÑ Í∏∞Î∞ò Îß§Ïπ≠ Í≤∞Í≥º ===\n",
      "                                            title_t0  \\\n",
      "0  dz-2384 has a superior preclinical profile to ...   \n",
      "1  jak2 regulates paclitaxel resistance in triple...   \n",
      "\n",
      "                                            title_t1  similarity  \\\n",
      "0  DZ-2384 has a superior preclinical profile to ...    0.826087   \n",
      "1  JAK2 regulates paclitaxel resistance in¬†triple...    0.800000   \n",
      "\n",
      "               drug_t0                                            drug_t1  \n",
      "0  dz-2384; paclitaxel  DOCETAXEL;PACLITAXEL;DZ-2384;METHOTREXATE;CHLO...  \n",
      "1           paclitaxel                             PACLITAXEL;GEMCITABINE  \n",
      "\n",
      "Drug Recall (Jaccard similarity ‚â• 0.8 Í∏∞Ï§Ä): 0.0000\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "\n",
    "# CSV Î∂àÎü¨Ïò§Í∏∞ (Ïù¥ÎØ∏ title Ï†ÑÏ≤òÎ¶¨ ÏôÑÎ£å)\n",
    "# t0: Ï†ïÎãµÏÖã, t1: ÏòàÏ∏°ÏÖã\n",
    "# t0 = pd.read_csv(\"t0.csv\")\n",
    "# t1 = pd.read_csv(\"t1.csv\")\n",
    "\n",
    "# 1Ô∏è‚É£ Jaccard Ïú†ÏÇ¨ÎèÑ Ìï®Ïàò (Îã®Ïñ¥ Îã®ÏúÑ)\n",
    "def jaccard_similarity(str1, str2):\n",
    "    set1 = set(str1.split())\n",
    "    set2 = set(str2.split())\n",
    "    if not set1 or not set2:\n",
    "        return 0\n",
    "    return len(set1 & set2) / len(set1 | set2)\n",
    "\n",
    "# threshold ÏÑ§Ï†ï\n",
    "threshold = 0.8\n",
    "\n",
    "# 2Ô∏è‚É£ Îß§Ïπ≠ Í≤∞Í≥º Ï†ÄÏû•\n",
    "matches = []\n",
    "\n",
    "for i, row0 in t0.iterrows():\n",
    "    for j, row1 in t1.iterrows():\n",
    "        sim = jaccard_similarity(row0[\"title\"], row1[\"title\"])\n",
    "        if sim >= threshold:\n",
    "            matches.append({\n",
    "                \"idx_t0\": i,\n",
    "                \"idx_t1\": j,\n",
    "                \"title_t0\": row0[\"title\"],\n",
    "                \"title_t1\": row1[\"title\"],\n",
    "                \"similarity\": sim,\n",
    "                \"drug_t0\": row0[\"drug\"],\n",
    "                \"drug_t1\": row1[\"drug\"]\n",
    "            })\n",
    "\n",
    "matched_df = pd.DataFrame(matches)\n",
    "\n",
    "# 3Ô∏è‚É£ Îß§Ïπ≠ Í≤∞Í≥º ÌôïÏù∏\n",
    "print(\"=== Title Ïú†ÏÇ¨ÎèÑ Í∏∞Î∞ò Îß§Ïπ≠ Í≤∞Í≥º ===\")\n",
    "print(matched_df[[\"title_t0\", \"title_t1\", \"similarity\", \"drug_t0\", \"drug_t1\"]].head())\n",
    "\n",
    "# 4Ô∏è‚É£ drug Ïû¨ÌòÑÏú® Í≥ÑÏÇ∞ (t0 Í∏∞Ï§Ä)\n",
    "matched_drugs = matched_df[\"drug_t0\"] == matched_df[\"drug_t1\"]\n",
    "recall = matched_drugs.sum() / t0[\"drug\"].nunique()\n",
    "\n",
    "print(f\"\\nDrug Recall (Jaccard similarity ‚â• {threshold} Í∏∞Ï§Ä): {recall:.4f}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "id": "3670cb3e",
   "metadata": {},
   "outputs": [],
   "source": [
    "# ÏïΩÎ¨º ÏÜåÎ¨∏ÏûêÎ°ú Î≥ÄÌôò ÌõÑ ; Í∏∞Ï§ÄÏúºÎ°ú Î¶¨Ïä§Ìä∏Ìôî\n",
    "def normalize_drug(drug_str):\n",
    "    return [d.strip().lower() for d in drug_str.split(\";\")]\n",
    "\n",
    "matched_df[\"drug_t0_list\"] = matched_df[\"drug_t0\"].apply(normalize_drug)\n",
    "matched_df[\"drug_t1_list\"] = matched_df[\"drug_t1\"].apply(normalize_drug)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "id": "0df2e1bc",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Drug Recall (Ïú†ÏÇ¨ title + drug Ìè¨Ìï® Í∏∞Ï§Ä): 0.0139\n"
     ]
    }
   ],
   "source": [
    "# drug overlap Ïó¨Î∂Ä ÌôïÏù∏\n",
    "matched_df[\"drug_overlap\"] = matched_df.apply(\n",
    "    lambda x: len(set(x[\"drug_t0_list\"]) & set(x[\"drug_t1_list\"])) > 0, axis=1\n",
    ")\n",
    "\n",
    "# t0 Í∏∞Ï§Ä Ïû¨ÌòÑÏú®\n",
    "recall = matched_df[\"drug_overlap\"].sum() / t0[\"drug\"].nunique()\n",
    "print(f\"Drug Recall (Ïú†ÏÇ¨ title + drug Ìè¨Ìï® Í∏∞Ï§Ä): {recall:.4f}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "id": "1e42df46",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Îß§Ïπ≠Îêú title Í∞úÏàò: 2\n",
      "Drug Recall (Ïú†ÏÇ¨ title + drug Ìè¨Ìï® Í∏∞Ï§Ä): 0.0139\n"
     ]
    }
   ],
   "source": [
    "# Îß§Ïπ≠Îêú title Í∞úÏàò\n",
    "matched_title_count = matched_df.shape[0]\n",
    "print(f\"Îß§Ïπ≠Îêú title Í∞úÏàò: {matched_title_count}\")\n",
    "\n",
    "# drug Ïû¨ÌòÑÏú®\n",
    "recall = matched_df[\"drug_overlap\"].sum() / t0[\"drug\"].nunique()\n",
    "print(f\"Drug Recall (Ïú†ÏÇ¨ title + drug Ìè¨Ìï® Í∏∞Ï§Ä): {recall:.4f}\")\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "1cac9a16",
   "metadata": {},
   "source": [
    "ÌÉÄÏù¥ÌãÄ Ïú†ÏÇ¨ÎèÑ ÎÇÆÏ∂îÍ∏∞"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "id": "f57ede6c",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Îß§Ïπ≠Îêú title Í∞úÏàò (threshold=0.6): 10\n"
     ]
    }
   ],
   "source": [
    "threshold = 0.6  # Ïú†ÏÇ¨ÎèÑ Í∏∞Ï§Ä ÎÇÆÏ∂§\n",
    "\n",
    "matches = []\n",
    "for i, row0 in t0.iterrows():\n",
    "    for j, row1 in t1.iterrows():\n",
    "        sim = jaccard_similarity(row0[\"title\"], row1[\"title\"])\n",
    "        if sim >= threshold:\n",
    "            matches.append({\n",
    "                \"idx_t0\": i,\n",
    "                \"idx_t1\": j,\n",
    "                \"title_t0\": row0[\"title\"],\n",
    "                \"title_t1\": row1[\"title\"],\n",
    "                \"similarity\": sim,\n",
    "                \"drug_t0\": row0[\"drug\"],\n",
    "                \"drug_t1\": row1[\"drug\"]\n",
    "            })\n",
    "\n",
    "matched_df = pd.DataFrame(matches)\n",
    "\n",
    "print(f\"Îß§Ïπ≠Îêú title Í∞úÏàò (threshold={threshold}): {matched_df.shape[0]}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "id": "960041b4",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "=== Îß§Ïπ≠Îêú title ÏòàÏãú ===\n",
      "                                            title_t0  \\\n",
      "0  conditionally reprogrammed colorectal cancer c...   \n",
      "1  evaluation of the efficacy of dasatinib, a src...   \n",
      "2  low?dose trametinib and bcl?xl antagonist have...   \n",
      "3  dz-2384 has a superior preclinical profile to ...   \n",
      "4  jak2 regulates paclitaxel resistance in triple...   \n",
      "5  acquired resistance to trastuzumab/pertuzumab ...   \n",
      "6  brca1-methylated triple negative breast cancer...   \n",
      "7  rb expression confers sensitivity to cdk4/6 in...   \n",
      "8  comparative study on the efficacy and exposure...   \n",
      "9  krt-232 and navitoclax enhance trametinib?ÏÖ≤ an...   \n",
      "\n",
      "                                            title_t1  similarity  \\\n",
      "0  Conditionally reprogrammed colorectal cancer c...    0.636364   \n",
      "1  Evaluation of the efficacy of dasatinib, a Src...    0.619048   \n",
      "2  Low‚Äëdose trametinib and Bcl‚ÄëxL antagonist have...    0.666667   \n",
      "3  DZ-2384 has a superior preclinical profile to ...    0.826087   \n",
      "4  JAK2 regulates paclitaxel resistance in¬†triple...    0.800000   \n",
      "5  Acquired resistance to trastuzumab/pertuzumab ...    0.619048   \n",
      "6  BRCA1-methylated triple negative breast cancer...    0.789474   \n",
      "7  RB expression confers sensitivity to CDK4/6 in...    0.600000   \n",
      "8  Comparative study on the efficacy and exposure...    0.760000   \n",
      "9  KRT-232 and navitoclax enhance trametinib‚Äôs an...    0.619048   \n",
      "\n",
      "                                             drug_t0  \\\n",
      "0      cetuximab; palbociclib; sorafenib; trametinib   \n",
      "1                                          dasatinib   \n",
      "2                                 abt263; trametinib   \n",
      "3                                dz-2384; paclitaxel   \n",
      "4                                         paclitaxel   \n",
      "5                   tas0728; trastuzumab; pertuzumab   \n",
      "6                              carboplatin; olaparib   \n",
      "7                           abemaciclib; palbociclib   \n",
      "8  afatinib; brigatinib; crizotinib; entrectinib;...   \n",
      "9            krt-232; krt232; navitoclax; trametinib   \n",
      "\n",
      "                                             drug_t1  \n",
      "0                                                  -  \n",
      "1                                          DASATINIB  \n",
      "2                                  TRAMETINIB;ABT263  \n",
      "3  DOCETAXEL;PACLITAXEL;DZ-2384;METHOTREXATE;CHLO...  \n",
      "4                             PACLITAXEL;GEMCITABINE  \n",
      "5  LAPATINIB;TRASTUZUMAB;PERTUZUMAB;TRASTUZUMAB E...  \n",
      "6                      OLAPARIB;4-CHLOROBENZOPHENONE  \n",
      "7                 PALBOCICLIB;RIBOCICLIB;ABEMACICLIB  \n",
      "8  GEFITINIB;OSIMERTINIB;AFATINIB;CRIZOTINIB;ENTR...  \n",
      "9                  TRAMETINIB;NAVITOCLAX;NAVTEMADLIN  \n"
     ]
    }
   ],
   "source": [
    "# Îß§Ïπ≠Îêú title 10Í∞ú ÌôïÏù∏\n",
    "print(\"=== Îß§Ïπ≠Îêú title ÏòàÏãú ===\")\n",
    "print(matched_df[[\"title_t0\", \"title_t1\", \"similarity\", \"drug_t0\", \"drug_t1\"]].head(10))\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "e5373291",
   "metadata": {},
   "source": [
    "ÌÉÄÏù¥ÌãÄ Ï†ÑÏ≤òÎ¶¨"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "id": "310cb001",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "=== t0 Ï†ÑÏ≤òÎ¶¨Îêú title ÏòàÏãú ===\n",
      "0    conditionally reprogrammed colorectal cancer c...\n",
      "1    combining mek and src inhibitors for treatment...\n",
      "2    sensitivity of kras mutant colorectal cancers ...\n",
      "3    targeting ras mutant colorectal cancer with du...\n",
      "4    mcl 1 inhibition overcomes intrinsic and acqui...\n",
      "Name: title, dtype: object\n",
      "\n",
      "=== t1 Ï†ÑÏ≤òÎ¶¨Îêú title ÏòàÏãú ===\n",
      "0    cdk4 6 inhibitors impede chemoresistance and i...\n",
      "1    conditionally reprogrammed colorectal cancer c...\n",
      "2    krt 232 and navitoclax enhance trametinib‚Äôs an...\n",
      "3    bgb 283 a novel raf kinase and egfr inhibitor ...\n",
      "4    acquired resistance to trastuzumab pertuzumab ...\n",
      "Name: title, dtype: object\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import re\n",
    "\n",
    "# CSV Î∂àÎü¨Ïò§Í∏∞\n",
    "# t0 = pd.read_csv(\"t0.csv\")\n",
    "# t1 = pd.read_csv(\"t1.csv\")\n",
    "\n",
    "# 1Ô∏è‚É£ title Ï†ÑÏ≤òÎ¶¨ Ìï®Ïàò\n",
    "def preprocess_title(title):\n",
    "    if pd.isna(title):\n",
    "        return \"\"\n",
    "    title = title.lower()  # ÏÜåÎ¨∏Ïûê ÌÜµÏùº\n",
    "    title = re.sub(r\"[\\-;,/():]\", \" \", title)  # ÌäπÏàòÎ¨∏Ïûê Ï†úÍ±∞\n",
    "    title = re.sub(r\"\\s+\", \" \", title)  # Í≥µÎ∞± ÌÜµÏùº\n",
    "    title = title.strip()\n",
    "    return title\n",
    "\n",
    "# 2Ô∏è‚É£ t0, t1Ïùò title Ïª¨Îüº Ï†ÑÏ≤òÎ¶¨\n",
    "t0[\"title\"] = t0[\"title\"].apply(preprocess_title)\n",
    "t1[\"title\"] = t1[\"title\"].apply(preprocess_title)\n",
    "\n",
    "# 3Ô∏è‚É£ Ï†ÑÏ≤òÎ¶¨ ÌôïÏù∏ (ÏÉÅÏúÑ 5Í∞ú)\n",
    "print(\"=== t0 Ï†ÑÏ≤òÎ¶¨Îêú title ÏòàÏãú ===\")\n",
    "print(t0[\"title\"].head())\n",
    "print(\"\\n=== t1 Ï†ÑÏ≤òÎ¶¨Îêú title ÏòàÏãú ===\")\n",
    "print(t1[\"title\"].head())\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "b5726365",
   "metadata": {},
   "source": [
    "title Í∏∞Ï§ÄÏúºÎ°ú Jaccard Ïú†ÏÇ¨ÎèÑ Í∏∞Î∞ò Îß§Ïπ≠ + drug Ïû¨ÌòÑÏú® Í≥ÑÏÇ∞"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "id": "e095955a",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Îß§Ïπ≠Îêú title Í∞úÏàò: 29\n",
      "                                            title_t0  \\\n",
      "0  conditionally reprogrammed colorectal cancer c...   \n",
      "1  activation of the mtor pathway by oxaliplatin ...   \n",
      "2  evaluation of the efficacy of dasatinib a src ...   \n",
      "3  bgb 283 a novel raf kinase and egfr inhibitor ...   \n",
      "4  synergistic anti tumor effect of mtor inhibito...   \n",
      "5  integrative in vivo drug testing using gene ex...   \n",
      "6  mtor inhibition and t dm1 in her2 positive bre...   \n",
      "7  dual fatty acid synthase and her2 signaling bl...   \n",
      "8  dz 2384 has a superior preclinical profile to ...   \n",
      "9  jak2 regulates paclitaxel resistance in triple...   \n",
      "\n",
      "                                            title_t1  similarity  \\\n",
      "0  conditionally reprogrammed colorectal cancer c...    1.000000   \n",
      "1  activation of the mtor pathway by oxaliplatin ...    1.000000   \n",
      "2  evaluation of the efficacy of dasatinib a src ...    0.842105   \n",
      "3  bgb 283 a novel raf kinase and egfr inhibitor ...    0.842105   \n",
      "4  synergistic anti tumor e ect of mtor inhibitor...    0.800000   \n",
      "5  integrative in vivo drug testing using gene ex...    1.000000   \n",
      "6  mtor inhibition and trastuzumab emtansine t dm...    0.833333   \n",
      "7  dual fatty acid synthase and her2 signaling bl...    1.000000   \n",
      "8  dz 2384 has a superior preclinical profile to ...    1.000000   \n",
      "9  jak2 regulates paclitaxel resistance in triple...    1.000000   \n",
      "\n",
      "                                             drug_t0  \\\n",
      "0      cetuximab; palbociclib; sorafenib; trametinib   \n",
      "1                            everolimus; oxaliplatin   \n",
      "2                                          dasatinib   \n",
      "3        bgb-283 (lifirafenib); cetuximab; erlotinib   \n",
      "4                   azd2014; irinotecan; oxaliplatin   \n",
      "5  bevacizumab; docetaxel; everolimus; neratinib;...   \n",
      "6                                  everolimus; t-md1   \n",
      "7                                 egcg; temsirolimus   \n",
      "8                                dz-2384; paclitaxel   \n",
      "9                                         paclitaxel   \n",
      "\n",
      "                                             drug_t1  drug_overlap  \n",
      "0                                                  -         False  \n",
      "1                             OXALIPLATIN;EVEROLIMUS          True  \n",
      "2                                          DASATINIB          True  \n",
      "3                   LIFIRAFENIB;DABRAFENIB;CETUXIMAB          True  \n",
      "4                             IRINOTECAN;VISTUSERTIB          True  \n",
      "5  SORAFENIB;EVEROLIMUS;DOCETAXEL;BEVACIZUMAB;PX-...          True  \n",
      "6                   EVEROLIMUS;TRASTUZUMAB EMTANSINE          True  \n",
      "7                   TRASTUZUMAB;LAPATINIB;PERTUZUMAB         False  \n",
      "8  DOCETAXEL;PACLITAXEL;DZ-2384;METHOTREXATE;CHLO...          True  \n",
      "9                             PACLITAXEL;GEMCITABINE          True  \n",
      "Drug Recall (Ïú†ÏÇ¨ title + drug Ìè¨Ìï® Í∏∞Ï§Ä): 0.1667\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import re\n",
    "\n",
    "# CSV Î∂àÎü¨Ïò§Í∏∞\n",
    "# t0 = pd.read_csv(\"t0.csv\")\n",
    "# t1 = pd.read_csv(\"t1.csv\")\n",
    "\n",
    "# 1Ô∏è‚É£ title Ï†ÑÏ≤òÎ¶¨\n",
    "def preprocess_title(title):\n",
    "    if pd.isna(title):\n",
    "        return \"\"\n",
    "    title = title.lower()  # ÏÜåÎ¨∏Ïûê ÌÜµÏùº\n",
    "    title = re.sub(r\"[\\-;,/():]\", \" \", title)  # ÌäπÏàòÎ¨∏Ïûê Ï†úÍ±∞\n",
    "    title = re.sub(r\"\\s+\", \" \", title)  # Í≥µÎ∞± ÌÜµÏùº\n",
    "    title = title.strip()\n",
    "    return title\n",
    "\n",
    "t0[\"title\"] = t0[\"title\"].apply(preprocess_title)\n",
    "t1[\"title\"] = t1[\"title\"].apply(preprocess_title)\n",
    "\n",
    "# 2Ô∏è‚É£ Jaccard Ïú†ÏÇ¨ÎèÑ Ìï®Ïàò\n",
    "def jaccard_similarity(str1, str2):\n",
    "    set1 = set(str1.split())\n",
    "    set2 = set(str2.split())\n",
    "    if not set1 or not set2:\n",
    "        return 0\n",
    "    return len(set1 & set2) / len(set1 | set2)\n",
    "\n",
    "threshold = 0.7  # Ïú†ÏÇ¨ÎèÑ Í∏∞Ï§Ä (Ï°∞Ï†ï Í∞ÄÎä•)\n",
    "\n",
    "# 3Ô∏è‚É£ title Ïú†ÏÇ¨ÎèÑ Í∏∞Î∞ò Îß§Ïπ≠\n",
    "matches = []\n",
    "for i, row0 in t0.iterrows():\n",
    "    for j, row1 in t1.iterrows():\n",
    "        sim = jaccard_similarity(row0[\"title\"], row1[\"title\"])\n",
    "        if sim >= threshold:\n",
    "            matches.append({\n",
    "                \"idx_t0\": i,\n",
    "                \"idx_t1\": j,\n",
    "                \"title_t0\": row0[\"title\"],\n",
    "                \"title_t1\": row1[\"title\"],\n",
    "                \"similarity\": sim,\n",
    "                \"drug_t0\": row0[\"drug\"],\n",
    "                \"drug_t1\": row1[\"drug\"]\n",
    "            })\n",
    "\n",
    "matched_df = pd.DataFrame(matches)\n",
    "\n",
    "# 4Ô∏è‚É£ drug Ï†ÑÏ≤òÎ¶¨ Î∞è Í≥µÌÜµ Ïó¨Î∂Ä ÌôïÏù∏\n",
    "def normalize_drug(drug_str):\n",
    "    if pd.isna(drug_str):\n",
    "        return []\n",
    "    return [d.strip().lower() for d in drug_str.split(\";\")]\n",
    "\n",
    "matched_df[\"drug_t0_list\"] = matched_df[\"drug_t0\"].apply(normalize_drug)\n",
    "matched_df[\"drug_t1_list\"] = matched_df[\"drug_t1\"].apply(normalize_drug)\n",
    "matched_df[\"drug_overlap\"] = matched_df.apply(\n",
    "    lambda x: len(set(x[\"drug_t0_list\"]) & set(x[\"drug_t1_list\"])) > 0, axis=1\n",
    ")\n",
    "\n",
    "# 5Ô∏è‚É£ Í≤∞Í≥º ÌôïÏù∏\n",
    "print(f\"Îß§Ïπ≠Îêú title Í∞úÏàò: {matched_df.shape[0]}\")\n",
    "print(matched_df[[\"title_t0\", \"title_t1\", \"similarity\", \"drug_t0\", \"drug_t1\", \"drug_overlap\"]].head(10))\n",
    "\n",
    "# 6Ô∏è‚É£ drug Ïû¨ÌòÑÏú® Í≥ÑÏÇ∞ (t0 Í∏∞Ï§Ä)\n",
    "recall = matched_df[\"drug_overlap\"].sum() / t0[\"drug\"].nunique()\n",
    "print(f\"Drug Recall (Ïú†ÏÇ¨ title + drug Ìè¨Ìï® Í∏∞Ï§Ä): {recall:.4f}\")\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "f4163b63",
   "metadata": {},
   "source": [
    "ÎìúÎü¨Í∑∏ Ïó¥ Ï†ÑÏ≤òÎ¶¨ + Î¶¨Ïä§Ìä∏Ìôî(ÏÖãÏúºÎ°ú Î¨∂Ïñ¥ Ïû¨ÌòÑÏú® Í≥ÑÏÇ∞ Í∞ÄÎä•)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "id": "274204f2",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "=== t0 Ï†ÑÏ≤òÎ¶¨Îêú drug ===\n",
      "                                            drug  \\\n",
      "0  cetuximab; palbociclib; sorafenib; trametinib   \n",
      "1                          dasatinib; trametinib   \n",
      "2                        palbociclib; trametinib   \n",
      "3                        palbociclib; trametinib   \n",
      "4                            regorafenib; s63845   \n",
      "\n",
      "                                         drug_list  \n",
      "0  [cetuximab, palbociclib, sorafenib, trametinib]  \n",
      "1                          [dasatinib, trametinib]  \n",
      "2                        [palbociclib, trametinib]  \n",
      "3                        [palbociclib, trametinib]  \n",
      "4                            [regorafenib, s63845]  \n",
      "\n",
      "=== t1 Ï†ÑÏ≤òÎ¶¨Îêú drug ===\n",
      "                                                drug  \\\n",
      "0                                      PALLADIUM;LEE   \n",
      "1                                                  -   \n",
      "2                  TRAMETINIB;NAVITOCLAX;NAVTEMADLIN   \n",
      "3                   LIFIRAFENIB;DABRAFENIB;CETUXIMAB   \n",
      "4  LAPATINIB;TRASTUZUMAB;PERTUZUMAB;TRASTUZUMAB E...   \n",
      "\n",
      "                                           drug_list  \n",
      "0                                   [palladium, lee]  \n",
      "1                                                [-]  \n",
      "2              [trametinib, navitoclax, navtemadlin]  \n",
      "3               [lifirafenib, dabrafenib, cetuximab]  \n",
      "4  [lapatinib, trastuzumab, pertuzumab, trastuzum...  \n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "\n",
    "# ÏòàÏãú: t0, t1 Ïù¥ÎØ∏ Î∂àÎü¨Ïò® ÏÉÅÌÉú\n",
    "# t0['drug'], t1['drug'] Ïª¨Îüº Ï°¥Ïû¨\n",
    "\n",
    "# 1Ô∏è‚É£ drug Ï†ÑÏ≤òÎ¶¨ Ìï®Ïàò\n",
    "def preprocess_drug(drug_str):\n",
    "    if pd.isna(drug_str):\n",
    "        return []\n",
    "    # ; Íµ¨Î∂Ñ, ÏÜåÎ¨∏Ïûê, Í≥µÎ∞± Ï†úÍ±∞\n",
    "    return [d.strip().lower() for d in drug_str.split(\";\") if d.strip()]\n",
    "\n",
    "# 2Ô∏è‚É£ t0, t1 drug Ïª¨Îüº Ï†ÑÏ≤òÎ¶¨\n",
    "t0[\"drug_list\"] = t0[\"drug\"].apply(preprocess_drug)\n",
    "t1[\"drug_list\"] = t1[\"drug\"].apply(preprocess_drug)\n",
    "\n",
    "# 3Ô∏è‚É£ Ï†ÑÏ≤òÎ¶¨ ÌôïÏù∏ (ÏÉÅÏúÑ 5Í∞ú)\n",
    "print(\"=== t0 Ï†ÑÏ≤òÎ¶¨Îêú drug ===\")\n",
    "print(t0[[\"drug\", \"drug_list\"]].head())\n",
    "print(\"\\n=== t1 Ï†ÑÏ≤òÎ¶¨Îêú drug ===\")\n",
    "print(t1[[\"drug\", \"drug_list\"]].head())\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "id": "079db414",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "                                            title_t0  \\\n",
      "0  conditionally reprogrammed colorectal cancer c...   \n",
      "1  activation of the mtor pathway by oxaliplatin ...   \n",
      "2  evaluation of the efficacy of dasatinib a src ...   \n",
      "3  bgb 283 a novel raf kinase and egfr inhibitor ...   \n",
      "4  synergistic anti tumor effect of mtor inhibito...   \n",
      "5  integrative in vivo drug testing using gene ex...   \n",
      "6  mtor inhibition and t dm1 in her2 positive bre...   \n",
      "7  dual fatty acid synthase and her2 signaling bl...   \n",
      "8  dz 2384 has a superior preclinical profile to ...   \n",
      "9  jak2 regulates paclitaxel resistance in triple...   \n",
      "\n",
      "                                            title_t1  \\\n",
      "0  conditionally reprogrammed colorectal cancer c...   \n",
      "1  activation of the mtor pathway by oxaliplatin ...   \n",
      "2  evaluation of the efficacy of dasatinib a src ...   \n",
      "3  bgb 283 a novel raf kinase and egfr inhibitor ...   \n",
      "4  synergistic anti tumor e ect of mtor inhibitor...   \n",
      "5  integrative in vivo drug testing using gene ex...   \n",
      "6  mtor inhibition and trastuzumab emtansine t dm...   \n",
      "7  dual fatty acid synthase and her2 signaling bl...   \n",
      "8  dz 2384 has a superior preclinical profile to ...   \n",
      "9  jak2 regulates paclitaxel resistance in triple...   \n",
      "\n",
      "                                        drug_t0_list  \\\n",
      "0    [cetuximab, palbociclib, sorafenib, trametinib]   \n",
      "1                          [everolimus, oxaliplatin]   \n",
      "2                                        [dasatinib]   \n",
      "3      [bgb-283 (lifirafenib), cetuximab, erlotinib]   \n",
      "4                 [azd2014, irinotecan, oxaliplatin]   \n",
      "5  [bevacizumab, docetaxel, everolimus, neratinib...   \n",
      "6                                [everolimus, t-md1]   \n",
      "7                               [egcg, temsirolimus]   \n",
      "8                              [dz-2384, paclitaxel]   \n",
      "9                                       [paclitaxel]   \n",
      "\n",
      "                                        drug_t1_list  drug_overlap_count  \\\n",
      "0                                                [-]                   0   \n",
      "1                          [oxaliplatin, everolimus]                   2   \n",
      "2                                        [dasatinib]                   1   \n",
      "3               [lifirafenib, dabrafenib, cetuximab]                   1   \n",
      "4                          [irinotecan, vistusertib]                   1   \n",
      "5  [sorafenib, everolimus, docetaxel, bevacizumab...                   6   \n",
      "6                [everolimus, trastuzumab emtansine]                   1   \n",
      "7               [trastuzumab, lapatinib, pertuzumab]                   0   \n",
      "8  [docetaxel, paclitaxel, dz-2384, methotrexate,...                   2   \n",
      "9                          [paclitaxel, gemcitabine]                   1   \n",
      "\n",
      "   drug_overlap_bool  \n",
      "0              False  \n",
      "1               True  \n",
      "2               True  \n",
      "3               True  \n",
      "4               True  \n",
      "5               True  \n",
      "6               True  \n",
      "7              False  \n",
      "8               True  \n",
      "9               True  \n",
      "Drug Recall (Ïú†ÏÇ¨ title + drug Îã®ÏúÑ Í∏∞Ï§Ä): 0.2553\n"
     ]
    }
   ],
   "source": [
    "# matched_df: title Ïú†ÏÇ¨ÎèÑ Í∏∞Î∞ò Îß§Ïπ≠ Í≤∞Í≥º DataFrame\n",
    "# Ïª¨Îüº: drug_t0_list, drug_t1_list (Î¶¨Ïä§Ìä∏ ÌòïÌÉú)\n",
    "\n",
    "# 1Ô∏è‚É£ Í∞Å Îß§Ïπ≠ÏóêÏÑú drug ÍµêÏßëÌï© Í∞úÏàò\n",
    "matched_df[\"drug_overlap_count\"] = matched_df.apply(\n",
    "    lambda x: len(set(x[\"drug_t0_list\"]) & set(x[\"drug_t1_list\"])), axis=1\n",
    ")\n",
    "\n",
    "# 2Ô∏è‚É£ ÍµêÏßëÌï©Ïù¥ 1Í∞ú Ïù¥ÏÉÅÏù¥Î©¥ True\n",
    "matched_df[\"drug_overlap_bool\"] = matched_df[\"drug_overlap_count\"] > 0\n",
    "\n",
    "# 3Ô∏è‚É£ Îß§Ïπ≠ Í≤∞Í≥º ÌôïÏù∏ (ÏÉÅÏúÑ 10Í∞ú)\n",
    "print(matched_df[[\"title_t0\", \"title_t1\", \"drug_t0_list\", \"drug_t1_list\", \"drug_overlap_count\", \"drug_overlap_bool\"]].head(10))\n",
    "\n",
    "# 4Ô∏è‚É£ Ï†ÑÏ≤¥ t0 ÏïΩÎ¨º Îã®ÏúÑ Í∏∞Ï§Ä Ïû¨ÌòÑÏú® Í≥ÑÏÇ∞\n",
    "t0_all_drugs = set([d for sublist in t0[\"drug_list\"] for d in sublist])\n",
    "\n",
    "# Îß§Ïπ≠Îêú ÏïΩÎ¨º ÏßëÌï©\n",
    "matched_drugs = set()\n",
    "for _, row in matched_df.iterrows():\n",
    "    matched_drugs.update(set(row[\"drug_t0_list\"]) & set(row[\"drug_t1_list\"]))\n",
    "\n",
    "drug_recall = len(matched_drugs) / len(t0_all_drugs)\n",
    "print(f\"Drug Recall (Ïú†ÏÇ¨ title + drug Îã®ÏúÑ Í∏∞Ï§Ä): {drug_recall:.4f}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "id": "7ee26024",
   "metadata": {},
   "outputs": [],
   "source": [
    "#\"ÌîÑÎ¶∞Ìä∏Î°ú ÌïòÎãà t0 Í≤∞Í≥ºÎßå ÎÇòÏôÄÏÑú ÏïÑÎûò displayÎ°ú Îã§Ïãú ÏΩîÎìúÏßÑÌñâ\"\n",
    "#=========================================================\n",
    "\n",
    "\n",
    "# from drugname_standardizer import DrugStandardizer\n",
    "\n",
    "# ds = DrugStandardizer()\n",
    "\n",
    "# def convert_to_generic(drug_list):\n",
    "#     return [ds.standardize_name(d) for d in drug_list]\n",
    "\n",
    "# # Î≥ÄÌôò Ï†ÅÏö©\n",
    "# t0[\"drug_list\"] = t0[\"drug_list\"].apply(convert_to_generic)\n",
    "# t1[\"drug_list\"] = t1[\"drug_list\"].apply(convert_to_generic)\n",
    "\n",
    "# # t0 Í≤∞Í≥º ÌôïÏù∏\n",
    "# print(\"=== t0 drug_list (generic Î≥ÄÌôò) ===\")\n",
    "# print(t0[[\"title\", \"drug_list\"]].head(10))\n",
    "\n",
    "# # t1 Í≤∞Í≥º ÌôïÏù∏\n",
    "# print(\"\\n=== t1 drug_list (generic Î≥ÄÌôò) ===\")\n",
    "# print(t1[[\"title\", \"drug_list\"]].head(10))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "id": "345e8f62",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Index(['drug', 'title', 'drug_list'], dtype='object')\n"
     ]
    }
   ],
   "source": [
    "print(t1.columns)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "id": "d4343404",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "=== t0 drug_list (generic Î≥ÄÌôò) ===\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>title</th>\n",
       "      <th>drug_list</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>conditionally reprogrammed colorectal cancer c...</td>\n",
       "      <td>[cetuximab, palbociclib, sorafenib, trametinib]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>combining mek and src inhibitors for treatment...</td>\n",
       "      <td>[dasatinib, trametinib]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>sensitivity of kras mutant colorectal cancers ...</td>\n",
       "      <td>[palbociclib, trametinib]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>targeting ras mutant colorectal cancer with du...</td>\n",
       "      <td>[palbociclib, trametinib]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>mcl 1 inhibition overcomes intrinsic and acqui...</td>\n",
       "      <td>[regorafenib, s63845]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>activation of the mtor pathway by oxaliplatin ...</td>\n",
       "      <td>[everolimus, oxaliplatin]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>synergistic effects of tetrandrine combined wi...</td>\n",
       "      <td>[tetrandrine]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>the synergistic antitumor effect of irinotecan...</td>\n",
       "      <td>[irinotecan (camptothecin)]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>synergistic tumor inhibition of colon cancer c...</td>\n",
       "      <td>[obeticholic acid, nitazoxanide]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>significant therapeutic efficacy with combined...</td>\n",
       "      <td>[cetuximab]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>effect of single and multiple administration o...</td>\n",
       "      <td>[temozolomide 100]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>synergistic killing of colorectal cancer cells...</td>\n",
       "      <td>[oxaliplatin]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>therapeutic efficacy and inhibitory mechanism ...</td>\n",
       "      <td>[regorafenib]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>phase ib study of vemurafenib in combination w...</td>\n",
       "      <td>[irinotecan, vemurafenib, cetuximab]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>evaluation of the efficacy of dasatinib a src ...</td>\n",
       "      <td>[dasatinib]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>dasatinib sensitizes kras mutant colorectal tu...</td>\n",
       "      <td>[cetuximab, dasatinib]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>regorafenib suppresses epidermal growth factor...</td>\n",
       "      <td>[regorafenib]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>therapeutic efficacy and inhibitory mechanism ...</td>\n",
       "      <td>[regorafenib]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>regorafenib inhibits colorectal tumor growth t...</td>\n",
       "      <td>[regorafenib]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>low?dose trametinib and bcl?xl antagonist have...</td>\n",
       "      <td>[abt263, trametinib]</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                title  \\\n",
       "0   conditionally reprogrammed colorectal cancer c...   \n",
       "1   combining mek and src inhibitors for treatment...   \n",
       "2   sensitivity of kras mutant colorectal cancers ...   \n",
       "3   targeting ras mutant colorectal cancer with du...   \n",
       "4   mcl 1 inhibition overcomes intrinsic and acqui...   \n",
       "5   activation of the mtor pathway by oxaliplatin ...   \n",
       "6   synergistic effects of tetrandrine combined wi...   \n",
       "7   the synergistic antitumor effect of irinotecan...   \n",
       "8   synergistic tumor inhibition of colon cancer c...   \n",
       "9   significant therapeutic efficacy with combined...   \n",
       "10  effect of single and multiple administration o...   \n",
       "11  synergistic killing of colorectal cancer cells...   \n",
       "12  therapeutic efficacy and inhibitory mechanism ...   \n",
       "13  phase ib study of vemurafenib in combination w...   \n",
       "14  evaluation of the efficacy of dasatinib a src ...   \n",
       "15  dasatinib sensitizes kras mutant colorectal tu...   \n",
       "16  regorafenib suppresses epidermal growth factor...   \n",
       "17  therapeutic efficacy and inhibitory mechanism ...   \n",
       "18  regorafenib inhibits colorectal tumor growth t...   \n",
       "19  low?dose trametinib and bcl?xl antagonist have...   \n",
       "\n",
       "                                          drug_list  \n",
       "0   [cetuximab, palbociclib, sorafenib, trametinib]  \n",
       "1                           [dasatinib, trametinib]  \n",
       "2                         [palbociclib, trametinib]  \n",
       "3                         [palbociclib, trametinib]  \n",
       "4                             [regorafenib, s63845]  \n",
       "5                         [everolimus, oxaliplatin]  \n",
       "6                                     [tetrandrine]  \n",
       "7                       [irinotecan (camptothecin)]  \n",
       "8                  [obeticholic acid, nitazoxanide]  \n",
       "9                                       [cetuximab]  \n",
       "10                               [temozolomide 100]  \n",
       "11                                    [oxaliplatin]  \n",
       "12                                    [regorafenib]  \n",
       "13             [irinotecan, vemurafenib, cetuximab]  \n",
       "14                                      [dasatinib]  \n",
       "15                           [cetuximab, dasatinib]  \n",
       "16                                    [regorafenib]  \n",
       "17                                    [regorafenib]  \n",
       "18                                    [regorafenib]  \n",
       "19                             [abt263, trametinib]  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "=== t1 drug_list (generic Î≥ÄÌôò) ===\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>title</th>\n",
       "      <th>drug_list</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>cdk4 6 inhibitors impede chemoresistance and i...</td>\n",
       "      <td>[palladium, lee]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>conditionally reprogrammed colorectal cancer c...</td>\n",
       "      <td>[-]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>krt 232 and navitoclax enhance trametinib‚Äôs an...</td>\n",
       "      <td>[trametinib, navitoclax, navtemadlin]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>bgb 283 a novel raf kinase and egfr inhibitor ...</td>\n",
       "      <td>[lifirafenib, dabrafenib, cetuximab]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>acquired resistance to trastuzumab pertuzumab ...</td>\n",
       "      <td>[lapatinib, trastuzumab, pertuzumab, trastuzum...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>integrative in vivo drug testing using gene ex...</td>\n",
       "      <td>[sorafenib, everolimus, docetaxel, bevacizumab...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>synergistic anti tumor e ect of mtor inhibitor...</td>\n",
       "      <td>[irinotecan, vistusertib]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>identification of src family kinases as potent...</td>\n",
       "      <td>[dasatinib, paclitaxel]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>evaluation of combined chemotherapy and genomi...</td>\n",
       "      <td>[sorafenib, gemcitabine, cisplatin, bevacizumab]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>mtor inhibition and trastuzumab emtansine t dm...</td>\n",
       "      <td>[everolimus, trastuzumab emtansine]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>overcoming osimertinib resistance with akt inh...</td>\n",
       "      <td>[osimertinib, capivasertib]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>oral estrogen receptor protac vepdegestrant ar...</td>\n",
       "      <td>[fulvestrant, azd-9496, vepdegestrant]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>sensitization of egfr wild type non small cell...</td>\n",
       "      <td>[cisplatin, erlotinib]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>cisplatin increases sensitivity to fgfr inhibi...</td>\n",
       "      <td>[cisplatin, infigratinib]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>exploration of immune modulatory effects of am...</td>\n",
       "      <td>[amivantamab, pembrolizumab]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>comparative study on the efficacy and exposure...</td>\n",
       "      <td>[gefitinib, osimertinib, afatinib, crizotinib,...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>mediator kinase inhibitors suppress triple neg...</td>\n",
       "      <td>[everolimus, cdk8/19i]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>dual fatty acid synthase and her2 signaling bl...</td>\n",
       "      <td>[trastuzumab, lapatinib, pertuzumab]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>dz 2384 has a superior preclinical profile to ...</td>\n",
       "      <td>[docetaxel, paclitaxel, dz-2384, methotrexate,...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>the iron chelator deferasirox synergises with ...</td>\n",
       "      <td>[doxorubicin, cisplatin, carboplatin, cyclopho...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                title  \\\n",
       "0   cdk4 6 inhibitors impede chemoresistance and i...   \n",
       "1   conditionally reprogrammed colorectal cancer c...   \n",
       "2   krt 232 and navitoclax enhance trametinib‚Äôs an...   \n",
       "3   bgb 283 a novel raf kinase and egfr inhibitor ...   \n",
       "4   acquired resistance to trastuzumab pertuzumab ...   \n",
       "5   integrative in vivo drug testing using gene ex...   \n",
       "6   synergistic anti tumor e ect of mtor inhibitor...   \n",
       "7   identification of src family kinases as potent...   \n",
       "8   evaluation of combined chemotherapy and genomi...   \n",
       "9   mtor inhibition and trastuzumab emtansine t dm...   \n",
       "10  overcoming osimertinib resistance with akt inh...   \n",
       "11  oral estrogen receptor protac vepdegestrant ar...   \n",
       "12  sensitization of egfr wild type non small cell...   \n",
       "13  cisplatin increases sensitivity to fgfr inhibi...   \n",
       "14  exploration of immune modulatory effects of am...   \n",
       "15  comparative study on the efficacy and exposure...   \n",
       "16  mediator kinase inhibitors suppress triple neg...   \n",
       "17  dual fatty acid synthase and her2 signaling bl...   \n",
       "18  dz 2384 has a superior preclinical profile to ...   \n",
       "19  the iron chelator deferasirox synergises with ...   \n",
       "\n",
       "                                            drug_list  \n",
       "0                                    [palladium, lee]  \n",
       "1                                                 [-]  \n",
       "2               [trametinib, navitoclax, navtemadlin]  \n",
       "3                [lifirafenib, dabrafenib, cetuximab]  \n",
       "4   [lapatinib, trastuzumab, pertuzumab, trastuzum...  \n",
       "5   [sorafenib, everolimus, docetaxel, bevacizumab...  \n",
       "6                           [irinotecan, vistusertib]  \n",
       "7                             [dasatinib, paclitaxel]  \n",
       "8    [sorafenib, gemcitabine, cisplatin, bevacizumab]  \n",
       "9                 [everolimus, trastuzumab emtansine]  \n",
       "10                        [osimertinib, capivasertib]  \n",
       "11             [fulvestrant, azd-9496, vepdegestrant]  \n",
       "12                             [cisplatin, erlotinib]  \n",
       "13                          [cisplatin, infigratinib]  \n",
       "14                       [amivantamab, pembrolizumab]  \n",
       "15  [gefitinib, osimertinib, afatinib, crizotinib,...  \n",
       "16                             [everolimus, cdk8/19i]  \n",
       "17               [trastuzumab, lapatinib, pertuzumab]  \n",
       "18  [docetaxel, paclitaxel, dz-2384, methotrexate,...  \n",
       "19  [doxorubicin, cisplatin, carboplatin, cyclopho...  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# t0 ÌôïÏù∏\n",
    "print(\"=== t0 drug_list (generic Î≥ÄÌôò) ===\")\n",
    "display(t0[[\"title\", \"drug_list\"]].head(20))  # Ï£ºÌîºÌÑ∞ ÌôòÍ≤ΩÏù¥Î©¥ display ÏÇ¨Ïö© Í∞ÄÎä•\n",
    "\n",
    "# t1 ÌôïÏù∏\n",
    "print(\"\\n=== t1 drug_list (generic Î≥ÄÌôò) ===\")\n",
    "display(t1[[\"title\", \"drug_list\"]].head(20))\n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "f1231496",
   "metadata": {},
   "source": [
    "Ï†ÑÏ≤òÎ¶¨Î∂ÄÌÑ∞ drug generic Î≥ÄÌôòÍπåÏßÄ Ìïú Î≤àÏóê pandas DataFrame ÎÇ¥ÏóêÏÑú Ï≤òÎ¶¨ÌïòÍ≥†, Î∞îÎ°ú title Îß§Ïπ≠ + drug Ïû¨ÌòÑÏú® Í≥ÑÏÇ∞"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "id": "77e7f854",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "=== Title Îß§Ïπ≠ Í≤∞Í≥º ===\n",
      "                                            title_t0  \\\n",
      "0  conditionally reprogrammed colorectal cancer c...   \n",
      "1  activation of the mtor pathway by oxaliplatin ...   \n",
      "2  evaluation of the efficacy of dasatinib a src ...   \n",
      "3  lowdose trametinib and bclxl antagonist have a...   \n",
      "4  bgb 283 a novel raf kinase and egfr inhibitor ...   \n",
      "5  synergistic anti tumor effect of mtor inhibito...   \n",
      "6  integrative in vivo drug testing using gene ex...   \n",
      "7  dual fatty acid synthase and her2 signaling bl...   \n",
      "8  dz 2384 has a superior preclinical profile to ...   \n",
      "9  jak2 regulates paclitaxel resistance in triple...   \n",
      "\n",
      "                                            title_t1  \\\n",
      "0  conditionally reprogrammed colorectal cancer c...   \n",
      "1  activation of the mtor pathway by oxaliplatin ...   \n",
      "2  evaluation of the efficacy of dasatinib a src ...   \n",
      "3  lowdose trametinib and bclxl antagonist have a...   \n",
      "4  bgb 283 a novel raf kinase and egfr inhibitor ...   \n",
      "5  synergistic anti tumor e ect of mtor inhibitor...   \n",
      "6  integrative in vivo drug testing using gene ex...   \n",
      "7  dual fatty acid synthase and her2 signaling bl...   \n",
      "8  dz 2384 has a superior preclinical profile to ...   \n",
      "9  jak2 regulates paclitaxel resistance in triple...   \n",
      "\n",
      "                                             drug_t0  \\\n",
      "0    [CETUXIMAB, PALBOCICLIB, SORAFENIB, TRAMETINIB]   \n",
      "1                          [EVEROLIMUS, OXALIPLATIN]   \n",
      "2                                        [DASATINIB]   \n",
      "3                               [abt263, TRAMETINIB]   \n",
      "4         [bgb283 lifirafenib, CETUXIMAB, ERLOTINIB]   \n",
      "5             [VISTUSERTIB, IRINOTECAN, OXALIPLATIN]   \n",
      "6  [BEVACIZUMAB, DOCETAXEL, EVEROLIMUS, NERATINIB...   \n",
      "7           [EPIGALLOCATECHIN GALLATE, TEMSIROLIMUS]   \n",
      "8                               [dz2384, PACLITAXEL]   \n",
      "9                                       [PACLITAXEL]   \n",
      "\n",
      "                                             drug_t1  similarity  \n",
      "0                                                 []    1.000000  \n",
      "1                          [OXALIPLATIN, EVEROLIMUS]    1.000000  \n",
      "2                                        [DASATINIB]    0.855331  \n",
      "3                               [TRAMETINIB, abt263]    1.000000  \n",
      "4               [LIFIRAFENIB, DABRAFENIB, CETUXIMAB]    0.880090  \n",
      "5                          [IRINOTECAN, VISTUSERTIB]    0.846991  \n",
      "6  [SORAFENIB, EVEROLIMUS, DOCETAXEL, BEVACIZUMAB...    1.000000  \n",
      "7               [TRASTUZUMAB, LAPATINIB, PERTUZUMAB]    1.000000  \n",
      "8  [DOCETAXEL, PACLITAXEL, dz2384, METHOTREXATE, ...    1.000000  \n",
      "9                          [PACLITAXEL, GEMCITABINE]    1.000000  \n",
      "\n",
      "Drug Recall (Ïú†ÏÇ¨ title + drug Ìè¨Ìï® Í∏∞Ï§Ä): 0.8276\n",
      "Matched Titles: 29 / 163\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import re\n",
    "from drugname_standardizer import DrugStandardizer\n",
    "from sklearn.feature_extraction.text import TfidfVectorizer\n",
    "from sklearn.metrics.pairwise import cosine_similarity\n",
    "\n",
    "# ======================================\n",
    "# 1Ô∏è‚É£ Ï†ÑÏ≤òÎ¶¨ Ìï®Ïàò\n",
    "# ======================================\n",
    "def preprocess_text(text):\n",
    "    if pd.isna(text):\n",
    "        return \"\"\n",
    "    text = text.lower()               # ÏÜåÎ¨∏Ïûê Î≥ÄÌôò\n",
    "    text = re.sub(r\"[^a-z0-9\\s]\", \"\", text)  # ÏïåÌååÎ≤≥, Ïà´Ïûê, Í≥µÎ∞± Ï†úÏô∏ Ï†úÍ±∞\n",
    "    text = re.sub(r\"\\s+\", \" \", text).strip() # Ïó∞ÏÜç Í≥µÎ∞± Ï†úÍ±∞\n",
    "    return text\n",
    "\n",
    "def preprocess_drug_list(drug_str):\n",
    "    if pd.isna(drug_str):\n",
    "        return []\n",
    "    return [preprocess_text(d) for d in drug_str.split(\";\")]\n",
    "\n",
    "# ======================================\n",
    "# 2Ô∏è‚É£ CSV Î∂àÎü¨Ïò§Í∏∞ (ÏòàÏãú)\n",
    "# ======================================\n",
    "# t0 = pd.read_csv(\"t0.csv\", encoding=\"utf-8\")\n",
    "# t1 = pd.read_csv(\"t1.csv\", encoding=\"utf-8\")\n",
    "\n",
    "# ======================================\n",
    "# 3Ô∏è‚É£ Ïª¨Îüº Ï†ÑÏ≤òÎ¶¨\n",
    "# ======================================\n",
    "for df in [t0, t1]:\n",
    "    df[\"title\"] = df[\"title\"].apply(preprocess_text)\n",
    "    df[\"drug_list\"] = df[\"drug\"].apply(preprocess_drug_list)\n",
    "\n",
    "# ======================================\n",
    "# 4Ô∏è‚É£ Drug Generic Î≥ÄÌôò\n",
    "# ======================================\n",
    "ds = DrugStandardizer()\n",
    "\n",
    "def convert_to_generic(drug_list):\n",
    "    return [ds.standardize_name(d) for d in drug_list]\n",
    "\n",
    "t0[\"drug_list\"] = t0[\"drug_list\"].apply(convert_to_generic)\n",
    "t1[\"drug_list\"] = t1[\"drug_list\"].apply(convert_to_generic)\n",
    "\n",
    "# ======================================\n",
    "# 5Ô∏è‚É£ Title Îß§Ïπ≠ (cosine similarity)\n",
    "# ======================================\n",
    "def match_titles(t0, t1, threshold=0.8):\n",
    "    vec = TfidfVectorizer().fit(t0[\"title\"].tolist() + t1[\"title\"].tolist())\n",
    "    t0_vec = vec.transform(t0[\"title\"])\n",
    "    t1_vec = vec.transform(t1[\"title\"])\n",
    "    \n",
    "    matches = []\n",
    "    for i, t0_row in t0.iterrows():\n",
    "        sims = cosine_similarity(t0_vec[i], t1_vec).flatten()\n",
    "        max_idx = sims.argmax()\n",
    "        if sims[max_idx] >= threshold:\n",
    "            matches.append({\n",
    "                \"title_t0\": t0_row[\"title\"],\n",
    "                \"title_t1\": t1.iloc[max_idx][\"title\"],\n",
    "                \"drug_t0\": t0_row[\"drug_list\"],\n",
    "                \"drug_t1\": t1.iloc[max_idx][\"drug_list\"],\n",
    "                \"similarity\": sims[max_idx]\n",
    "            })\n",
    "    return pd.DataFrame(matches)\n",
    "\n",
    "matched_df = match_titles(t0, t1, threshold=0.8)\n",
    "\n",
    "# ======================================\n",
    "# 6Ô∏è‚É£ Drug Recall Í≥ÑÏÇ∞\n",
    "# ======================================\n",
    "def compute_drug_recall(matched_df):\n",
    "    true_positives = 0\n",
    "    for _, row in matched_df.iterrows():\n",
    "        if any(d in row[\"drug_t1\"] for d in row[\"drug_t0\"]):\n",
    "            true_positives += 1\n",
    "    recall = true_positives / len(matched_df) if len(matched_df) > 0 else 0\n",
    "    return recall\n",
    "\n",
    "drug_recall = compute_drug_recall(matched_df)\n",
    "\n",
    "# ======================================\n",
    "# 7Ô∏è‚É£ Í≤∞Í≥º ÌôïÏù∏\n",
    "# ======================================\n",
    "print(\"=== Title Îß§Ïπ≠ Í≤∞Í≥º ===\")\n",
    "print(matched_df.head(10))\n",
    "print(f\"\\nDrug Recall (Ïú†ÏÇ¨ title + drug Ìè¨Ìï® Í∏∞Ï§Ä): {drug_recall:.4f}\")\n",
    "print(f\"Matched Titles: {len(matched_df)} / {len(t0)}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "id": "8f852416",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "=== Drug Overlap True/False ===\n",
      "                                            title_t0  \\\n",
      "0  conditionally reprogrammed colorectal cancer c...   \n",
      "1  activation of the mtor pathway by oxaliplatin ...   \n",
      "2  evaluation of the efficacy of dasatinib a src ...   \n",
      "3  lowdose trametinib and bclxl antagonist have a...   \n",
      "4  bgb 283 a novel raf kinase and egfr inhibitor ...   \n",
      "5  synergistic anti tumor effect of mtor inhibito...   \n",
      "6  integrative in vivo drug testing using gene ex...   \n",
      "7  dual fatty acid synthase and her2 signaling bl...   \n",
      "8  dz 2384 has a superior preclinical profile to ...   \n",
      "9  jak2 regulates paclitaxel resistance in triple...   \n",
      "\n",
      "                                            title_t1  \\\n",
      "0  conditionally reprogrammed colorectal cancer c...   \n",
      "1  activation of the mtor pathway by oxaliplatin ...   \n",
      "2  evaluation of the efficacy of dasatinib a src ...   \n",
      "3  lowdose trametinib and bclxl antagonist have a...   \n",
      "4  bgb 283 a novel raf kinase and egfr inhibitor ...   \n",
      "5  synergistic anti tumor e ect of mtor inhibitor...   \n",
      "6  integrative in vivo drug testing using gene ex...   \n",
      "7  dual fatty acid synthase and her2 signaling bl...   \n",
      "8  dz 2384 has a superior preclinical profile to ...   \n",
      "9  jak2 regulates paclitaxel resistance in triple...   \n",
      "\n",
      "                                             drug_t0  \\\n",
      "0    [CETUXIMAB, PALBOCICLIB, SORAFENIB, TRAMETINIB]   \n",
      "1                          [EVEROLIMUS, OXALIPLATIN]   \n",
      "2                                        [DASATINIB]   \n",
      "3                               [abt263, TRAMETINIB]   \n",
      "4         [bgb283 lifirafenib, CETUXIMAB, ERLOTINIB]   \n",
      "5             [VISTUSERTIB, IRINOTECAN, OXALIPLATIN]   \n",
      "6  [BEVACIZUMAB, DOCETAXEL, EVEROLIMUS, NERATINIB...   \n",
      "7           [EPIGALLOCATECHIN GALLATE, TEMSIROLIMUS]   \n",
      "8                               [dz2384, PACLITAXEL]   \n",
      "9                                       [PACLITAXEL]   \n",
      "\n",
      "                                             drug_t1  drug_overlap  \n",
      "0                                                 []         False  \n",
      "1                          [OXALIPLATIN, EVEROLIMUS]          True  \n",
      "2                                        [DASATINIB]          True  \n",
      "3                               [TRAMETINIB, abt263]          True  \n",
      "4               [LIFIRAFENIB, DABRAFENIB, CETUXIMAB]          True  \n",
      "5                          [IRINOTECAN, VISTUSERTIB]          True  \n",
      "6  [SORAFENIB, EVEROLIMUS, DOCETAXEL, BEVACIZUMAB...          True  \n",
      "7               [TRASTUZUMAB, LAPATINIB, PERTUZUMAB]         False  \n",
      "8  [DOCETAXEL, PACLITAXEL, dz2384, METHOTREXATE, ...          True  \n",
      "9                          [PACLITAXEL, GEMCITABINE]          True  \n",
      "\n",
      "Drug Recall (drug ÍµêÏßëÌï© 1Í∞ú Ïù¥ÏÉÅ Í∏∞Ï§Ä): 0.8276\n"
     ]
    }
   ],
   "source": [
    "from drugname_standardizer import DrugStandardizer\n",
    "\n",
    "# ======================================\n",
    "# 1Ô∏è‚É£ Drug Generic Î≥ÄÌôò\n",
    "# ======================================\n",
    "ds = DrugStandardizer()\n",
    "\n",
    "def convert_to_generic(drug_list):\n",
    "    # ';' Íµ¨Î∂Ñ Î¶¨Ïä§Ìä∏Î•º Î∞õÏïÑÏÑú genericÏúºÎ°ú Î≥ÄÌôò\n",
    "    return [ds.standardize_name(d) for d in drug_list]\n",
    "\n",
    "# Í∏∞Ï°¥ drug Ïª¨ÎüºÏù¥ ; Íµ¨Î∂Ñ Î¨∏ÏûêÏó¥Ïù¥ÎùºÍ≥† Í∞ÄÏ†ï\n",
    "t0[\"drug_list\"] = t0[\"drug\"].str.split(\";\").apply(convert_to_generic)\n",
    "t1[\"drug_list\"] = t1[\"drug\"].str.split(\";\").apply(convert_to_generic)\n",
    "\n",
    "# ======================================\n",
    "# 2Ô∏è‚É£ True/False Í≥ÑÏÇ∞ (drug ÍµêÏßëÌï© Ï°¥Ïû¨ Ïó¨Î∂Ä)\n",
    "# ======================================\n",
    "def drug_overlap(row):\n",
    "    return any(d in row[\"drug_t1\"] for d in row[\"drug_t0\"])\n",
    "\n",
    "# matched_dfÎäî title Îß§Ïπ≠ ÌõÑ ÏÉùÏÑ±Îêú DataFrame\n",
    "# matched_df = pd.DataFrame({\n",
    "#     \"title_t0\": [...], \"title_t1\": [...],\n",
    "#     \"drug_t0\": t0_drug_list, \"drug_t1\": t1_drug_list\n",
    "# })\n",
    "\n",
    "matched_df[\"drug_overlap\"] = matched_df.apply(drug_overlap, axis=1)\n",
    "\n",
    "# ======================================\n",
    "# 3Ô∏è‚É£ Ïû¨ÌòÑÏú® Í≥ÑÏÇ∞\n",
    "# ======================================\n",
    "true_positives = matched_df[\"drug_overlap\"].sum()\n",
    "drug_recall = true_positives / len(matched_df) if len(matched_df) > 0 else 0\n",
    "\n",
    "# ======================================\n",
    "# 4Ô∏è‚É£ Í≤∞Í≥º ÌôïÏù∏\n",
    "# ======================================\n",
    "print(\"=== Drug Overlap True/False ===\")\n",
    "print(matched_df[[\"title_t0\", \"title_t1\", \"drug_t0\", \"drug_t1\", \"drug_overlap\"]].head(10))\n",
    "print(f\"\\nDrug Recall (drug ÍµêÏßëÌï© 1Í∞ú Ïù¥ÏÉÅ Í∏∞Ï§Ä): {drug_recall:.4f}\")\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "a460ae34",
   "metadata": {},
   "source": [
    "Í∞Å Îã®Í≥Ñ Í≤ÄÏ¶ù ÎπÑÍµêÌïòÎ©¥ÏÑú Í≥ÑÏÇ∞ "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "id": "638053c6",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "=== t0 Ï†ÑÏ≤òÎ¶¨ ÌôïÏù∏ ===\n",
      "                                               title  \\\n",
      "0  conditionally reprogrammed colorectal cancer c...   \n",
      "1  combining mek and src inhibitors for treatment...   \n",
      "2  sensitivity of kras mutant colorectal cancers ...   \n",
      "3  targeting ras mutant colorectal cancer with du...   \n",
      "4  mcl 1 inhibition overcomes intrinsic and acqui...   \n",
      "\n",
      "                                         drug_list  \n",
      "0  [cetuximab, palbociclib, sorafenib, trametinib]  \n",
      "1                          [dasatinib, trametinib]  \n",
      "2                        [palbociclib, trametinib]  \n",
      "3                        [palbociclib, trametinib]  \n",
      "4                            [regorafenib, s63845]  \n",
      "=== t1 Ï†ÑÏ≤òÎ¶¨ ÌôïÏù∏ ===\n",
      "                                               title  \\\n",
      "0  cdk4 6 inhibitors impede chemoresistance and i...   \n",
      "1  conditionally reprogrammed colorectal cancer c...   \n",
      "2  krt 232 and navitoclax enhance trametinibs ant...   \n",
      "3  bgb 283 a novel raf kinase and egfr inhibitor ...   \n",
      "4  acquired resistance to trastuzumab pertuzumab ...   \n",
      "\n",
      "                                           drug_list  \n",
      "0                                   [PALLADIUM, LEE]  \n",
      "1                                                [-]  \n",
      "2              [TRAMETINIB, NAVITOCLAX, NAVTEMADLIN]  \n",
      "3               [LIFIRAFENIB, DABRAFENIB, CETUXIMAB]  \n",
      "4  [LAPATINIB, TRASTUZUMAB, PERTUZUMAB, TRASTUZUM...  \n",
      "\n",
      "=== t0 drug_list generic Î≥ÄÌôò ÌôïÏù∏ ===\n",
      "                                            drug  \\\n",
      "0  cetuximab; palbociclib; sorafenib; trametinib   \n",
      "1                          dasatinib; trametinib   \n",
      "2                        palbociclib; trametinib   \n",
      "3                        palbociclib; trametinib   \n",
      "4                            regorafenib; s63845   \n",
      "\n",
      "                                         drug_list  \n",
      "0  [CETUXIMAB, PALBOCICLIB, SORAFENIB, TRAMETINIB]  \n",
      "1                          [DASATINIB, TRAMETINIB]  \n",
      "2                        [PALBOCICLIB, TRAMETINIB]  \n",
      "3                        [PALBOCICLIB, TRAMETINIB]  \n",
      "4                            [REGORAFENIB, s63845]  \n",
      "\n",
      "=== t1 drug_list generic Î≥ÄÌôò ÌôïÏù∏ ===\n",
      "                                                drug  \\\n",
      "0                                      PALLADIUM;LEE   \n",
      "1                                                  -   \n",
      "2                  TRAMETINIB;NAVITOCLAX;NAVTEMADLIN   \n",
      "3                   LIFIRAFENIB;DABRAFENIB;CETUXIMAB   \n",
      "4  LAPATINIB;TRASTUZUMAB;PERTUZUMAB;TRASTUZUMAB E...   \n",
      "\n",
      "                                           drug_list  \n",
      "0                                   [PALLADIUM, LEE]  \n",
      "1                                                [-]  \n",
      "2              [TRAMETINIB, NAVITOCLAX, NAVTEMADLIN]  \n",
      "3               [LIFIRAFENIB, DABRAFENIB, CETUXIMAB]  \n",
      "4  [LAPATINIB, TRASTUZUMAB, PERTUZUMAB, TRASTUZUM...  \n",
      "\n",
      "=== Title Îß§Ïπ≠ Í≤∞Í≥º ÌôïÏù∏ ===\n",
      "                                            title_t0  \\\n",
      "0  conditionally reprogrammed colorectal cancer c...   \n",
      "1  activation of the mtor pathway by oxaliplatin ...   \n",
      "2  evaluation of the efficacy of dasatinib a src ...   \n",
      "3  lowdose trametinib and bclxl antagonist have a...   \n",
      "4  bgb 283 a novel raf kinase and egfr inhibitor ...   \n",
      "5  synergistic anti tumor effect of mtor inhibito...   \n",
      "6  integrative in vivo drug testing using gene ex...   \n",
      "7  dual fatty acid synthase and her2 signaling bl...   \n",
      "8  dz 2384 has a superior preclinical profile to ...   \n",
      "9  jak2 regulates paclitaxel resistance in triple...   \n",
      "\n",
      "                                            title_t1  \\\n",
      "0  conditionally reprogrammed colorectal cancer c...   \n",
      "1  activation of the mtor pathway by oxaliplatin ...   \n",
      "2  evaluation of the efficacy of dasatinib a src ...   \n",
      "3  lowdose trametinib and bclxl antagonist have a...   \n",
      "4  bgb 283 a novel raf kinase and egfr inhibitor ...   \n",
      "5  synergistic anti tumor e ect of mtor inhibitor...   \n",
      "6  integrative in vivo drug testing using gene ex...   \n",
      "7  dual fatty acid synthase and her2 signaling bl...   \n",
      "8  dz 2384 has a superior preclinical profile to ...   \n",
      "9  jak2 regulates paclitaxel resistance in triple...   \n",
      "\n",
      "                                             drug_t0  \\\n",
      "0    [CETUXIMAB, PALBOCICLIB, SORAFENIB, TRAMETINIB]   \n",
      "1                          [EVEROLIMUS, OXALIPLATIN]   \n",
      "2                                        [DASATINIB]   \n",
      "3                               [abt263, TRAMETINIB]   \n",
      "4      [bgb-283 (lifirafenib), CETUXIMAB, ERLOTINIB]   \n",
      "5             [VISTUSERTIB, IRINOTECAN, OXALIPLATIN]   \n",
      "6  [BEVACIZUMAB, DOCETAXEL, EVEROLIMUS, NERATINIB...   \n",
      "7           [EPIGALLOCATECHIN GALLATE, TEMSIROLIMUS]   \n",
      "8                              [dz-2384, PACLITAXEL]   \n",
      "9                                       [PACLITAXEL]   \n",
      "\n",
      "                                             drug_t1  similarity  \n",
      "0                                                [-]    1.000000  \n",
      "1                          [OXALIPLATIN, EVEROLIMUS]    1.000000  \n",
      "2                                        [DASATINIB]    0.855331  \n",
      "3                               [TRAMETINIB, ABT263]    1.000000  \n",
      "4               [LIFIRAFENIB, DABRAFENIB, CETUXIMAB]    0.880090  \n",
      "5                          [IRINOTECAN, VISTUSERTIB]    0.846991  \n",
      "6  [SORAFENIB, EVEROLIMUS, DOCETAXEL, BEVACIZUMAB...    1.000000  \n",
      "7               [TRASTUZUMAB, LAPATINIB, PERTUZUMAB]    1.000000  \n",
      "8  [DOCETAXEL, PACLITAXEL, DZ-2384, METHOTREXATE,...    1.000000  \n",
      "9                          [PACLITAXEL, GEMCITABINE]    1.000000  \n",
      "\n",
      "=== Drug Overlap True/False ÌôïÏù∏ ===\n",
      "                                             drug_t0  \\\n",
      "0    [CETUXIMAB, PALBOCICLIB, SORAFENIB, TRAMETINIB]   \n",
      "1                          [EVEROLIMUS, OXALIPLATIN]   \n",
      "2                                        [DASATINIB]   \n",
      "3                               [abt263, TRAMETINIB]   \n",
      "4      [bgb-283 (lifirafenib), CETUXIMAB, ERLOTINIB]   \n",
      "5             [VISTUSERTIB, IRINOTECAN, OXALIPLATIN]   \n",
      "6  [BEVACIZUMAB, DOCETAXEL, EVEROLIMUS, NERATINIB...   \n",
      "7           [EPIGALLOCATECHIN GALLATE, TEMSIROLIMUS]   \n",
      "8                              [dz-2384, PACLITAXEL]   \n",
      "9                                       [PACLITAXEL]   \n",
      "\n",
      "                                             drug_t1  drug_overlap  \n",
      "0                                                [-]         False  \n",
      "1                          [OXALIPLATIN, EVEROLIMUS]          True  \n",
      "2                                        [DASATINIB]          True  \n",
      "3                               [TRAMETINIB, ABT263]          True  \n",
      "4               [LIFIRAFENIB, DABRAFENIB, CETUXIMAB]          True  \n",
      "5                          [IRINOTECAN, VISTUSERTIB]          True  \n",
      "6  [SORAFENIB, EVEROLIMUS, DOCETAXEL, BEVACIZUMAB...          True  \n",
      "7               [TRASTUZUMAB, LAPATINIB, PERTUZUMAB]         False  \n",
      "8  [DOCETAXEL, PACLITAXEL, DZ-2384, METHOTREXATE,...          True  \n",
      "9                          [PACLITAXEL, GEMCITABINE]          True  \n",
      "\n",
      "Drug Recall (drug ÍµêÏßëÌï© 1Í∞ú Ïù¥ÏÉÅ Í∏∞Ï§Ä): 0.8276\n",
      "Matched Titles: 29 / 163\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import re\n",
    "from drugname_standardizer import DrugStandardizer\n",
    "from sklearn.feature_extraction.text import TfidfVectorizer\n",
    "from sklearn.metrics.pairwise import cosine_similarity\n",
    "\n",
    "# ======================================\n",
    "# 1Ô∏è‚É£ Ï†ÑÏ≤òÎ¶¨ Ìï®Ïàò\n",
    "# ======================================\n",
    "def preprocess_text(text):\n",
    "    if pd.isna(text):\n",
    "        return \"\"\n",
    "    text = text.lower()\n",
    "    text = re.sub(r\"[^a-z0-9\\s]\", \"\", text)\n",
    "    text = re.sub(r\"\\s+\", \" \", text).strip()\n",
    "    return text\n",
    "\n",
    "def preprocess_drug_list(drug_str):\n",
    "    if pd.isna(drug_str):\n",
    "        return []\n",
    "    return [d.strip() for d in drug_str.split(\";\") if d.strip()]\n",
    "\n",
    "# ======================================\n",
    "# 2Ô∏è‚É£ CSV Î∂àÎü¨Ïò§Í∏∞ (ÏòàÏãú)\n",
    "# ======================================\n",
    "# t0 = pd.read_csv(\"t0.csv\", encoding=\"utf-8\")\n",
    "# t1 = pd.read_csv(\"t1.csv\", encoding=\"utf-8\")\n",
    "\n",
    "# ======================================\n",
    "# 3Ô∏è‚É£ Ïª¨Îüº Ï†ÑÏ≤òÎ¶¨\n",
    "# ======================================\n",
    "for df_name, df in zip([\"t0\", \"t1\"], [t0, t1]):\n",
    "    df[\"title\"] = df[\"title\"].apply(preprocess_text)\n",
    "    df[\"drug_list\"] = df[\"drug\"].apply(preprocess_drug_list)\n",
    "    print(f\"=== {df_name} Ï†ÑÏ≤òÎ¶¨ ÌôïÏù∏ ===\")\n",
    "    print(df[[\"title\", \"drug_list\"]].head(5))\n",
    "\n",
    "# ======================================\n",
    "# 4Ô∏è‚É£ Drug Generic Î≥ÄÌôò\n",
    "# ======================================\n",
    "ds = DrugStandardizer()\n",
    "\n",
    "def convert_to_generic(drug_list):\n",
    "    return [ds.standardize_name(d) for d in drug_list]\n",
    "\n",
    "t0[\"drug_list\"] = t0[\"drug_list\"].apply(convert_to_generic)\n",
    "t1[\"drug_list\"] = t1[\"drug_list\"].apply(convert_to_generic)\n",
    "\n",
    "print(\"\\n=== t0 drug_list generic Î≥ÄÌôò ÌôïÏù∏ ===\")\n",
    "print(t0[[\"drug\", \"drug_list\"]].head(5))\n",
    "print(\"\\n=== t1 drug_list generic Î≥ÄÌôò ÌôïÏù∏ ===\")\n",
    "print(t1[[\"drug\", \"drug_list\"]].head(5))\n",
    "\n",
    "# ======================================\n",
    "# 5Ô∏è‚É£ Title Îß§Ïπ≠ (cosine similarity)\n",
    "# ======================================\n",
    "def match_titles(t0, t1, threshold=0.8):\n",
    "    vec = TfidfVectorizer().fit(t0[\"title\"].tolist() + t1[\"title\"].tolist())\n",
    "    t0_vec = vec.transform(t0[\"title\"])\n",
    "    t1_vec = vec.transform(t1[\"title\"])\n",
    "    \n",
    "    matches = []\n",
    "    for i, t0_row in t0.iterrows():\n",
    "        sims = cosine_similarity(t0_vec[i], t1_vec).flatten()\n",
    "        max_idx = sims.argmax()\n",
    "        if sims[max_idx] >= threshold:\n",
    "            matches.append({\n",
    "                \"title_t0\": t0_row[\"title\"],\n",
    "                \"title_t1\": t1.iloc[max_idx][\"title\"],\n",
    "                \"drug_t0\": t0_row[\"drug_list\"],\n",
    "                \"drug_t1\": t1.iloc[max_idx][\"drug_list\"],\n",
    "                \"similarity\": sims[max_idx]\n",
    "            })\n",
    "    return pd.DataFrame(matches)\n",
    "\n",
    "matched_df = match_titles(t0, t1, threshold=0.8)\n",
    "print(\"\\n=== Title Îß§Ïπ≠ Í≤∞Í≥º ÌôïÏù∏ ===\")\n",
    "print(matched_df.head(10))\n",
    "\n",
    "# ======================================\n",
    "# 6Ô∏è‚É£ Drug ÍµêÏßëÌï© True/False\n",
    "# ======================================\n",
    "def drug_overlap(row):\n",
    "    return any(d in row[\"drug_t1\"] for d in row[\"drug_t0\"])\n",
    "\n",
    "matched_df[\"drug_overlap\"] = matched_df.apply(drug_overlap, axis=1)\n",
    "print(\"\\n=== Drug Overlap True/False ÌôïÏù∏ ===\")\n",
    "print(matched_df[[\"drug_t0\", \"drug_t1\", \"drug_overlap\"]].head(10))\n",
    "\n",
    "# ======================================\n",
    "# 7Ô∏è‚É£ Drug Recall Í≥ÑÏÇ∞\n",
    "# ======================================\n",
    "true_positives = matched_df[\"drug_overlap\"].sum()\n",
    "drug_recall = true_positives / len(matched_df) if len(matched_df) > 0 else 0\n",
    "print(f\"\\nDrug Recall (drug ÍµêÏßëÌï© 1Í∞ú Ïù¥ÏÉÅ Í∏∞Ï§Ä): {drug_recall:.4f}\")\n",
    "print(f\"Matched Titles: {len(matched_df)} / {len(t0)}\")\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "6adc2d45",
   "metadata": {},
   "source": [
    "Î¶¨ÏΩúÎ∂ÄÎ∂Ñ Í≤∞Í≥º ÏÑ∏ÏÑ∏Ìûà "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "id": "3fc32664",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "====================================\n",
      "Title T0: conditionally reprogrammed colorectal cancer cells combined with mouse avatars identify synergy between egfr and mek or cdk4 6 inhibitors\n",
      "Title T1: conditionally reprogrammed colorectal cancer cells combined with mouse avatars identify synergy between egfr and mek or cdk4 6 inhibitors\n",
      "Drug T0: ['CETUXIMAB', 'PALBOCICLIB', 'SORAFENIB', 'TRAMETINIB']\n",
      "Drug T1: ['-']\n",
      "Overlap: False\n",
      "====================================\n",
      "Title T0: activation of the mtor pathway by oxaliplatin in the treatment of colorectal cancer liver metastasis\n",
      "Title T1: activation of the mtor pathway by oxaliplatin in the treatment of colorectal cancer liver metastasis\n",
      "Drug T0: ['EVEROLIMUS', 'OXALIPLATIN']\n",
      "Drug T1: ['OXALIPLATIN', 'EVEROLIMUS']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: evaluation of the efficacy of dasatinib a src abl inhibitor in colorectal cancer cell lines and explant mouse model\n",
      "Title T1: evaluation of the efficacy of dasatinib a src abl inhibitor in colorectal cancer cell lines and explant mousemodel\n",
      "Drug T0: ['DASATINIB']\n",
      "Drug T1: ['DASATINIB']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: lowdose trametinib and bclxl antagonist have a specific antitumor effect in krasmutated colorectal cancer cells\n",
      "Title T1: lowdose trametinib and bclxl antagonist have a specific antitumor effect in krasmutated colorectal cancer cells\n",
      "Drug T0: ['abt263', 'TRAMETINIB']\n",
      "Drug T1: ['TRAMETINIB', 'ABT263']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: bgb 283 a novel raf kinase and egfr inhibitor displays potent antitumor activity inbraf mutated colorectal cancers\n",
      "Title T1: bgb 283 a novel raf kinase and egfr inhibitor displays potent antitumor activity in braf mutated colorectal cancers\n",
      "Drug T0: ['bgb-283 (lifirafenib)', 'CETUXIMAB', 'ERLOTINIB']\n",
      "Drug T1: ['LIFIRAFENIB', 'DABRAFENIB', 'CETUXIMAB']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: synergistic anti tumor effect of mtor inhibitors with irinotecan on colon cancer cells\n",
      "Title T1: synergistic anti tumor e ect of mtor inhibitors with irinotecan on colon cancer cells\n",
      "Drug T0: ['VISTUSERTIB', 'IRINOTECAN', 'OXALIPLATIN']\n",
      "Drug T1: ['IRINOTECAN', 'VISTUSERTIB']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: integrative in vivo drug testing using gene expression signature and patient derived xenografts from treatment refractory her2 positive and triple negative subtypes of breast cancer\n",
      "Title T1: integrative in vivo drug testing using gene expression signature and patient derived xenografts from treatment refractory her2 positive and triple negative subtypes of breast cancer\n",
      "Drug T0: ['BEVACIZUMAB', 'DOCETAXEL', 'EVEROLIMUS', 'NERATINIB', 'PX-478', 'SORAFENIB']\n",
      "Drug T1: ['SORAFENIB', 'EVEROLIMUS', 'DOCETAXEL', 'BEVACIZUMAB', 'PX-478', 'NERATINIB']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: dual fatty acid synthase and her2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti her2 drugs\n",
      "Title T1: dual fatty acid synthase and her2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti her2 drugs\n",
      "Drug T0: ['EPIGALLOCATECHIN GALLATE', 'TEMSIROLIMUS']\n",
      "Drug T1: ['TRASTUZUMAB', 'LAPATINIB', 'PERTUZUMAB']\n",
      "Overlap: False\n",
      "====================================\n",
      "Title T0: dz 2384 has a superior preclinical profile to taxanes for the treatment of triple negative breast cancer and is synergistic with anti ctla 4 immunotherapy\n",
      "Title T1: dz 2384 has a superior preclinical profile to taxanes for the treatment of triple negative breast cancer and is synergistic with anti ctla 4 immunotherapy\n",
      "Drug T0: ['dz-2384', 'PACLITAXEL']\n",
      "Drug T1: ['DOCETAXEL', 'PACLITAXEL', 'DZ-2384', 'METHOTREXATE', 'CHLORAMBUCIL', 'anthracyclines', 'RITONAVIR', 'ELACRIDAR', 'SORAFENIB', 'FULVESTRANT', 'SUNITINIB', 'NIVOLUMAB', 'PEMBROLIZUMAB']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: jak2 regulates paclitaxel resistance in triple negative breast cancers\n",
      "Title T1: jak2 regulates paclitaxel resistance in triple negative breast cancers\n",
      "Drug T0: ['PACLITAXEL']\n",
      "Drug T1: ['PACLITAXEL', 'GEMCITABINE']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: wnt catenin inhibition disrupts carboplatin resistance in isogenic models of triple negative breast cancer\n",
      "Title T1: wnt catenin inhibition disrupts carboplatin resistance in isogenic models of triple negative breast cancer\n",
      "Drug T0: ['CARBOPLATIN', 'WNT-974']\n",
      "Drug T1: ['CARBOPLATIN', 'Wnt inhibitor', 'CHIR', 'DIMETHYL SULFOXIDE']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: acquired resistance to trastuzumab pertuzumab or to t dm1 in vivo can be overcome by her2 kinase inhibition with tas0728\n",
      "Title T1: acquired resistance to trastuzumab pertuzumab or to t dm1 in vivo can be overcome by her2 kinase inhibition with tas0728\n",
      "Drug T0: ['tas0728', 'TRASTUZUMAB', 'PERTUZUMAB']\n",
      "Drug T1: ['LAPATINIB', 'TRASTUZUMAB', 'PERTUZUMAB', 'TRASTUZUMAB EMTANSINE', 'TAS0728']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: the iron chelator deferasirox synergises with chemotherapy to treat triple negative breast cancers\n",
      "Title T1: the iron chelator deferasirox synergises with chemotherapy to treat triple negative breast cancers\n",
      "Drug T0: ['adriamycin (doxorubicin)', 'dfx', 'CYCLOPHOSPHAMIDE']\n",
      "Drug T1: ['DOXORUBICIN', 'CISPLATIN', 'CARBOPLATIN', 'CYCLOPHOSPHAMIDE', 'DEFERASIROX']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: identification of src family kinases as potential therapeutic targets for chemotherapy resistant triple negative breast cancer\n",
      "Title T1: identification of src family kinases as potential therapeutic targets for chemotherapy resistant triple negative breast cancer\n",
      "Drug T0: ['DASATINIB', 'PACLITAXEL']\n",
      "Drug T1: ['DASATINIB', 'PACLITAXEL']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: evaluation of combined chemotherapy and genomic driven targeted therapy in patient derived xenografts identifies new therapeutic approaches in squamous non small cell lung cancer patients\n",
      "Title T1: evaluation of combined chemotherapy and genomic driven targeted therapy in patient derived xenografts identifies new therapeutic approaches in squamous non small cell lung cancer patients\n",
      "Drug T0: ['CARBOPLATIN', 'CISPLATIN', 'ETOPOSIDE', 'GEMCITABINE', 'PACLITAXEL', 'PEMETREXED']\n",
      "Drug T1: ['SORAFENIB', 'GEMCITABINE', 'CISPLATIN', 'BEVACIZUMAB']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: cdk4 6 inhibitors impede chemoresistance and inhibit tumor growth of small cell lung cancer\n",
      "Title T1: cdk4 6 inhibitors impede chemoresistance and inhibit tumor growth of small cell lung cancer\n",
      "Drug T0: ['CISPLATIN', 'ETOPOSIDE']\n",
      "Drug T1: ['PALLADIUM', 'LEE']\n",
      "Overlap: False\n",
      "====================================\n",
      "Title T0: cisplatin increases sensitivity to fgfr inhibition in patient derived xenograft models of lung squamous cell carcinoma\n",
      "Title T1: cisplatin increases sensitivity to fgfr inhibition in patient derived xenograft models of lung squamous cell carcinoma\n",
      "Drug T0: ['INFIGRATINIB', 'CISPLATIN']\n",
      "Drug T1: ['CISPLATIN', 'INFIGRATINIB']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: sensitization of egfr wild type nonsmall cell lung cancer cells to egfr tyrosine kinase inhibitor erlotinib\n",
      "Title T1: sensitization of egfr wild type non small cell lung cancer cells to egfr tyrosine kinase inhibitor erlotinib\n",
      "Drug T0: ['CISPLATIN', 'ERLOTINIB']\n",
      "Drug T1: ['CISPLATIN', 'ERLOTINIB']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: oral estrogen receptor protac vepdegestrant arv 471 is highly efficacious as monotherapy and in combination with cdk4 6 or pi3k mtor pathway inhibitors in preclinical erbreast cancer models\n",
      "Title T1: oral estrogen receptor protac vepdegestrant arv 471 is highly efficacious as monotherapy and in combination with cdk4 6 or pi3k mtor pathway inhibitors in preclinical er breast cancer models\n",
      "Drug T0: ['FULVESTRANT']\n",
      "Drug T1: ['FULVESTRANT', 'AZD-9496', 'VEPDEGESTRANT']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: her4 affects sensitivity to tamoxifen and abemaciclib in luminal breast cancer cells and restricts tumor growth in mcf 7 based humanized tumor mice\n",
      "Title T1: her4affects sensitivity to tamoxifen and abemaciclib in luminal breast cancer cells and restricts tumor growth in mcf 7 based humanized tumor mice\n",
      "Drug T0: ['ABEMACICLIB', 'TAMOXIFEN']\n",
      "Drug T1: ['RITUXIMAB', 'PEMBROLIZUMAB', 'NIVOLUMAB', 'FULVESTRANT', 'SUNITINIB']\n",
      "Overlap: False\n",
      "====================================\n",
      "Title T0: mediator kinase inhibitors suppress triple negative breast cancer growth and extend tumor suppression by mtor and akt inhibitors\n",
      "Title T1: mediator kinase inhibitors suppress triple negative breast cancer growth and extend tumor suppression by mtor and akt inhibitors\n",
      "Drug T0: ['CAPIVASERTIB', 'EVEROLIMUS']\n",
      "Drug T1: ['EVEROLIMUS', 'CDK8/19i']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: brca1 methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form rad51 foci and respond poorly to olaparib\n",
      "Title T1: brca1 methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form rad51 foci and respond poorly to olaparib\n",
      "Drug T0: ['CARBOPLATIN', 'OLAPARIB']\n",
      "Drug T1: ['OLAPARIB', '4-CHLOROBENZOPHENONE']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: rb expression confers sensitivity to cdk4 6 inhibitormediated radiosensitization across breast cancer subtypes\n",
      "Title T1: rb expression confers sensitivity to cdk4 6 inhibitormediated radiosensitization across breast cancer subtypes\n",
      "Drug T0: ['ABEMACICLIB', 'PALBOCICLIB']\n",
      "Drug T1: ['PALBOCICLIB', 'RIBOCICLIB', 'ABEMACICLIB']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: comparative study on the efficacy and exposure of molecular target agents in nonsmall cell lung cancer pdx models with driver genetic alterations\n",
      "Title T1: comparative study on the efficacy and exposure of molecular target agents in non small cell lung cancer pdx models with driver genetic alterations\n",
      "Drug T0: ['AFATINIB', 'BRIGATINIB', 'CRIZOTINIB', 'ENTRECTINIB', 'GEFITINIB', 'LORLATINIB', 'OSIMERTINIB']\n",
      "Drug T1: ['GEFITINIB', 'OSIMERTINIB', 'AFATINIB', 'CRIZOTINIB', 'ENTRECTINIB', 'BRIGATINIB', 'LORLATINIB', 'POZIOTINIB', 'TRASTUZUMAB DERUXTECAN']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: the lifted veil of uncommon egfr mutation pl747p in non small cell lung cancer molecular feature and targeting sensitivity to tyrosine kinase inhibitors\n",
      "Title T1: the lifted veil of uncommon egfr mutation pl747p in non small cell lung cancer molecular feature and targeting sensitivity to tyrosine kinase inhibitors\n",
      "Drug T0: ['AFATINIB', 'DACOMITINIB', 'OSIMERTINIB']\n",
      "Drug T1: ['ERLOTINIB', 'GEFITINIB', 'OSIMERTINIB', 'AFATINIB']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: overcoming osimertinib resistance with akt inhibition in egfrm driven nonsmall cell lung cancer with pik3ca pten alterations\n",
      "Title T1: overcoming osimertinib resistance with akt inhibition in egfrm driven nonsmall cell lung cancer with pik3ca pten alterations\n",
      "Drug T0: ['CAPIVASERTIB', 'OSIMERTINIB']\n",
      "Drug T1: ['OSIMERTINIB', 'CAPIVASERTIB']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: evaluation of combined chemotherapy and genomic driven targeted therapy in patient derived xenografts identifies new therapeutic approaches in squamous non small cell lung cancer patients\n",
      "Title T1: evaluation of combined chemotherapy and genomic driven targeted therapy in patient derived xenografts identifies new therapeutic approaches in squamous non small cell lung cancer patients\n",
      "Drug T0: ['AFATINIB', 'TRAMETINIB']\n",
      "Drug T1: ['SORAFENIB', 'GEMCITABINE', 'CISPLATIN', 'BEVACIZUMAB']\n",
      "Overlap: False\n",
      "====================================\n",
      "Title T0: exploration of immune modulatory effects of amivantamab in combination with pembrolizumab in lung and head and neck squamous cell carcinoma\n",
      "Title T1: exploration of immune modulatory effects of amivantamab in combination with pembrolizumab in lung and head and neck squamous cell carcinoma\n",
      "Drug T0: ['PEMBROLIZUMAB', 'AMIVANTAMAB']\n",
      "Drug T1: ['AMIVANTAMAB', 'PEMBROLIZUMAB']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: krt 232 and navitoclax enhance trametinib anti cancer activity in non small cell lung cancer patient derived xenografts with kras mutations\n",
      "Title T1: krt 232 and navitoclax enhance trametinibs anti cancer activity in non small cell lung cancer patient derived xenografts with kras mutations\n",
      "Drug T0: ['NAVTEMADLIN', 'krt232', 'NAVITOCLAX', 'TRAMETINIB']\n",
      "Drug T1: ['TRAMETINIB', 'NAVITOCLAX', 'NAVTEMADLIN']\n",
      "Overlap: True\n",
      "\n",
      "====================================\n",
      "Drug Recall (drug ÍµêÏßëÌï© 1Í∞ú Ïù¥ÏÉÅ Í∏∞Ï§Ä): 0.8276\n",
      "Matched Titles: 29 / 163\n"
     ]
    }
   ],
   "source": [
    "# ======================================\n",
    "# 1Ô∏è‚É£ Drug ÍµêÏßëÌï© True/False ÌôïÏù∏\n",
    "# ======================================\n",
    "def drug_overlap(row):\n",
    "    # drug_t0ÏôÄ drug_t1 Î¶¨Ïä§Ìä∏ Í∞Ñ ÌïòÎÇòÎùºÎèÑ Í≤πÏπòÎ©¥ True\n",
    "    overlap = any(d in row[\"drug_t1\"] for d in row[\"drug_t0\"])\n",
    "    print(\"====================================\")\n",
    "    print(f\"Title T0: {row['title_t0']}\")\n",
    "    print(f\"Title T1: {row['title_t1']}\")\n",
    "    print(f\"Drug T0: {row['drug_t0']}\")\n",
    "    print(f\"Drug T1: {row['drug_t1']}\")\n",
    "    print(f\"Overlap: {overlap}\")\n",
    "    return overlap\n",
    "\n",
    "matched_df[\"drug_overlap\"] = matched_df.apply(drug_overlap, axis=1)\n",
    "\n",
    "# ======================================\n",
    "# 2Ô∏è‚É£ Drug Recall Í≥ÑÏÇ∞\n",
    "# ======================================\n",
    "true_positives = matched_df[\"drug_overlap\"].sum()\n",
    "drug_recall = true_positives / len(matched_df) if len(matched_df) > 0 else 0\n",
    "\n",
    "print(\"\\n====================================\")\n",
    "print(f\"Drug Recall (drug ÍµêÏßëÌï© 1Í∞ú Ïù¥ÏÉÅ Í∏∞Ï§Ä): {drug_recall:.4f}\")\n",
    "print(f\"Matched Titles: {len(matched_df)} / {len(t0)}\")\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "9d42a2bb",
   "metadata": {},
   "source": [
    "Ï†ÑÏ≤¥Ìñâ ÏàòÍ∏∞Ï∑§"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "id": "77ef08ec",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "====================================\n",
      "Index: 0\n",
      "Title T0: conditionally reprogrammed colorectal cancer cells combined with mouse avatars identify synergy between egfr and mek or cdk4 6 inhibitors\n",
      "Title T1: conditionally reprogrammed colorectal cancer cells combined with mouse avatars identify synergy between egfr and mek or cdk4 6 inhibitors\n",
      "Drug T0 (Generic): ['CETUXIMAB', 'PALBOCICLIB', 'SORAFENIB', 'TRAMETINIB']\n",
      "Drug T1 (Generic): ['-']\n",
      "Overlap: False\n",
      "====================================\n",
      "Index: 1\n",
      "Title T0: activation of the mtor pathway by oxaliplatin in the treatment of colorectal cancer liver metastasis\n",
      "Title T1: activation of the mtor pathway by oxaliplatin in the treatment of colorectal cancer liver metastasis\n",
      "Drug T0 (Generic): ['EVEROLIMUS', 'OXALIPLATIN']\n",
      "Drug T1 (Generic): ['OXALIPLATIN', 'EVEROLIMUS']\n",
      "Overlap: True\n",
      "====================================\n",
      "Index: 2\n",
      "Title T0: evaluation of the efficacy of dasatinib a src abl inhibitor in colorectal cancer cell lines and explant mouse model\n",
      "Title T1: evaluation of the efficacy of dasatinib a src abl inhibitor in colorectal cancer cell lines and explant mousemodel\n",
      "Drug T0 (Generic): ['DASATINIB']\n",
      "Drug T1 (Generic): ['DASATINIB']\n",
      "Overlap: True\n",
      "====================================\n",
      "Index: 3\n",
      "Title T0: lowdose trametinib and bclxl antagonist have a specific antitumor effect in krasmutated colorectal cancer cells\n",
      "Title T1: lowdose trametinib and bclxl antagonist have a specific antitumor effect in krasmutated colorectal cancer cells\n",
      "Drug T0 (Generic): ['abt263', 'TRAMETINIB']\n",
      "Drug T1 (Generic): ['TRAMETINIB', 'ABT263']\n",
      "Overlap: True\n",
      "====================================\n",
      "Index: 4\n",
      "Title T0: bgb 283 a novel raf kinase and egfr inhibitor displays potent antitumor activity inbraf mutated colorectal cancers\n",
      "Title T1: bgb 283 a novel raf kinase and egfr inhibitor displays potent antitumor activity in braf mutated colorectal cancers\n",
      "Drug T0 (Generic): ['bgb-283 (lifirafenib)', 'CETUXIMAB', 'ERLOTINIB']\n",
      "Drug T1 (Generic): ['LIFIRAFENIB', 'DABRAFENIB', 'CETUXIMAB']\n",
      "Overlap: True\n",
      "====================================\n",
      "Index: 5\n",
      "Title T0: synergistic anti tumor effect of mtor inhibitors with irinotecan on colon cancer cells\n",
      "Title T1: synergistic anti tumor e ect of mtor inhibitors with irinotecan on colon cancer cells\n",
      "Drug T0 (Generic): ['VISTUSERTIB', 'IRINOTECAN', 'OXALIPLATIN']\n",
      "Drug T1 (Generic): ['IRINOTECAN', 'VISTUSERTIB']\n",
      "Overlap: True\n",
      "====================================\n",
      "Index: 6\n",
      "Title T0: integrative in vivo drug testing using gene expression signature and patient derived xenografts from treatment refractory her2 positive and triple negative subtypes of breast cancer\n",
      "Title T1: integrative in vivo drug testing using gene expression signature and patient derived xenografts from treatment refractory her2 positive and triple negative subtypes of breast cancer\n",
      "Drug T0 (Generic): ['BEVACIZUMAB', 'DOCETAXEL', 'EVEROLIMUS', 'NERATINIB', 'PX-478', 'SORAFENIB']\n",
      "Drug T1 (Generic): ['SORAFENIB', 'EVEROLIMUS', 'DOCETAXEL', 'BEVACIZUMAB', 'PX-478', 'NERATINIB']\n",
      "Overlap: True\n",
      "====================================\n",
      "Index: 7\n",
      "Title T0: dual fatty acid synthase and her2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti her2 drugs\n",
      "Title T1: dual fatty acid synthase and her2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti her2 drugs\n",
      "Drug T0 (Generic): ['EPIGALLOCATECHIN GALLATE', 'TEMSIROLIMUS']\n",
      "Drug T1 (Generic): ['TRASTUZUMAB', 'LAPATINIB', 'PERTUZUMAB']\n",
      "Overlap: False\n",
      "====================================\n",
      "Index: 8\n",
      "Title T0: dz 2384 has a superior preclinical profile to taxanes for the treatment of triple negative breast cancer and is synergistic with anti ctla 4 immunotherapy\n",
      "Title T1: dz 2384 has a superior preclinical profile to taxanes for the treatment of triple negative breast cancer and is synergistic with anti ctla 4 immunotherapy\n",
      "Drug T0 (Generic): ['dz-2384', 'PACLITAXEL']\n",
      "Drug T1 (Generic): ['DOCETAXEL', 'PACLITAXEL', 'DZ-2384', 'METHOTREXATE', 'CHLORAMBUCIL', 'anthracyclines', 'RITONAVIR', 'ELACRIDAR', 'SORAFENIB', 'FULVESTRANT', 'SUNITINIB', 'NIVOLUMAB', 'PEMBROLIZUMAB']\n",
      "Overlap: True\n",
      "====================================\n",
      "Index: 9\n",
      "Title T0: jak2 regulates paclitaxel resistance in triple negative breast cancers\n",
      "Title T1: jak2 regulates paclitaxel resistance in triple negative breast cancers\n",
      "Drug T0 (Generic): ['PACLITAXEL']\n",
      "Drug T1 (Generic): ['PACLITAXEL', 'GEMCITABINE']\n",
      "Overlap: True\n",
      "====================================\n",
      "Index: 10\n",
      "Title T0: wnt catenin inhibition disrupts carboplatin resistance in isogenic models of triple negative breast cancer\n",
      "Title T1: wnt catenin inhibition disrupts carboplatin resistance in isogenic models of triple negative breast cancer\n",
      "Drug T0 (Generic): ['CARBOPLATIN', 'WNT-974']\n",
      "Drug T1 (Generic): ['CARBOPLATIN', 'Wnt inhibitor', 'CHIR', 'DIMETHYL SULFOXIDE']\n",
      "Overlap: True\n",
      "====================================\n",
      "Index: 11\n",
      "Title T0: acquired resistance to trastuzumab pertuzumab or to t dm1 in vivo can be overcome by her2 kinase inhibition with tas0728\n",
      "Title T1: acquired resistance to trastuzumab pertuzumab or to t dm1 in vivo can be overcome by her2 kinase inhibition with tas0728\n",
      "Drug T0 (Generic): ['tas0728', 'TRASTUZUMAB', 'PERTUZUMAB']\n",
      "Drug T1 (Generic): ['LAPATINIB', 'TRASTUZUMAB', 'PERTUZUMAB', 'TRASTUZUMAB EMTANSINE', 'TAS0728']\n",
      "Overlap: True\n",
      "====================================\n",
      "Index: 12\n",
      "Title T0: the iron chelator deferasirox synergises with chemotherapy to treat triple negative breast cancers\n",
      "Title T1: the iron chelator deferasirox synergises with chemotherapy to treat triple negative breast cancers\n",
      "Drug T0 (Generic): ['adriamycin (doxorubicin)', 'dfx', 'CYCLOPHOSPHAMIDE']\n",
      "Drug T1 (Generic): ['DOXORUBICIN', 'CISPLATIN', 'CARBOPLATIN', 'CYCLOPHOSPHAMIDE', 'DEFERASIROX']\n",
      "Overlap: True\n",
      "====================================\n",
      "Index: 13\n",
      "Title T0: identification of src family kinases as potential therapeutic targets for chemotherapy resistant triple negative breast cancer\n",
      "Title T1: identification of src family kinases as potential therapeutic targets for chemotherapy resistant triple negative breast cancer\n",
      "Drug T0 (Generic): ['DASATINIB', 'PACLITAXEL']\n",
      "Drug T1 (Generic): ['DASATINIB', 'PACLITAXEL']\n",
      "Overlap: True\n",
      "====================================\n",
      "Index: 14\n",
      "Title T0: evaluation of combined chemotherapy and genomic driven targeted therapy in patient derived xenografts identifies new therapeutic approaches in squamous non small cell lung cancer patients\n",
      "Title T1: evaluation of combined chemotherapy and genomic driven targeted therapy in patient derived xenografts identifies new therapeutic approaches in squamous non small cell lung cancer patients\n",
      "Drug T0 (Generic): ['CARBOPLATIN', 'CISPLATIN', 'ETOPOSIDE', 'GEMCITABINE', 'PACLITAXEL', 'PEMETREXED']\n",
      "Drug T1 (Generic): ['SORAFENIB', 'GEMCITABINE', 'CISPLATIN', 'BEVACIZUMAB']\n",
      "Overlap: True\n",
      "====================================\n",
      "Index: 15\n",
      "Title T0: cdk4 6 inhibitors impede chemoresistance and inhibit tumor growth of small cell lung cancer\n",
      "Title T1: cdk4 6 inhibitors impede chemoresistance and inhibit tumor growth of small cell lung cancer\n",
      "Drug T0 (Generic): ['CISPLATIN', 'ETOPOSIDE']\n",
      "Drug T1 (Generic): ['PALLADIUM', 'LEE']\n",
      "Overlap: False\n",
      "====================================\n",
      "Index: 16\n",
      "Title T0: cisplatin increases sensitivity to fgfr inhibition in patient derived xenograft models of lung squamous cell carcinoma\n",
      "Title T1: cisplatin increases sensitivity to fgfr inhibition in patient derived xenograft models of lung squamous cell carcinoma\n",
      "Drug T0 (Generic): ['INFIGRATINIB', 'CISPLATIN']\n",
      "Drug T1 (Generic): ['CISPLATIN', 'INFIGRATINIB']\n",
      "Overlap: True\n",
      "====================================\n",
      "Index: 17\n",
      "Title T0: sensitization of egfr wild type nonsmall cell lung cancer cells to egfr tyrosine kinase inhibitor erlotinib\n",
      "Title T1: sensitization of egfr wild type non small cell lung cancer cells to egfr tyrosine kinase inhibitor erlotinib\n",
      "Drug T0 (Generic): ['CISPLATIN', 'ERLOTINIB']\n",
      "Drug T1 (Generic): ['CISPLATIN', 'ERLOTINIB']\n",
      "Overlap: True\n",
      "====================================\n",
      "Index: 18\n",
      "Title T0: oral estrogen receptor protac vepdegestrant arv 471 is highly efficacious as monotherapy and in combination with cdk4 6 or pi3k mtor pathway inhibitors in preclinical erbreast cancer models\n",
      "Title T1: oral estrogen receptor protac vepdegestrant arv 471 is highly efficacious as monotherapy and in combination with cdk4 6 or pi3k mtor pathway inhibitors in preclinical er breast cancer models\n",
      "Drug T0 (Generic): ['FULVESTRANT']\n",
      "Drug T1 (Generic): ['FULVESTRANT', 'AZD-9496', 'VEPDEGESTRANT']\n",
      "Overlap: True\n",
      "====================================\n",
      "Index: 19\n",
      "Title T0: her4 affects sensitivity to tamoxifen and abemaciclib in luminal breast cancer cells and restricts tumor growth in mcf 7 based humanized tumor mice\n",
      "Title T1: her4affects sensitivity to tamoxifen and abemaciclib in luminal breast cancer cells and restricts tumor growth in mcf 7 based humanized tumor mice\n",
      "Drug T0 (Generic): ['ABEMACICLIB', 'TAMOXIFEN']\n",
      "Drug T1 (Generic): ['RITUXIMAB', 'PEMBROLIZUMAB', 'NIVOLUMAB', 'FULVESTRANT', 'SUNITINIB']\n",
      "Overlap: False\n",
      "====================================\n",
      "Index: 20\n",
      "Title T0: mediator kinase inhibitors suppress triple negative breast cancer growth and extend tumor suppression by mtor and akt inhibitors\n",
      "Title T1: mediator kinase inhibitors suppress triple negative breast cancer growth and extend tumor suppression by mtor and akt inhibitors\n",
      "Drug T0 (Generic): ['CAPIVASERTIB', 'EVEROLIMUS']\n",
      "Drug T1 (Generic): ['EVEROLIMUS', 'CDK8/19i']\n",
      "Overlap: True\n",
      "====================================\n",
      "Index: 21\n",
      "Title T0: brca1 methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form rad51 foci and respond poorly to olaparib\n",
      "Title T1: brca1 methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form rad51 foci and respond poorly to olaparib\n",
      "Drug T0 (Generic): ['CARBOPLATIN', 'OLAPARIB']\n",
      "Drug T1 (Generic): ['OLAPARIB', '4-CHLOROBENZOPHENONE']\n",
      "Overlap: True\n",
      "====================================\n",
      "Index: 22\n",
      "Title T0: rb expression confers sensitivity to cdk4 6 inhibitormediated radiosensitization across breast cancer subtypes\n",
      "Title T1: rb expression confers sensitivity to cdk4 6 inhibitormediated radiosensitization across breast cancer subtypes\n",
      "Drug T0 (Generic): ['ABEMACICLIB', 'PALBOCICLIB']\n",
      "Drug T1 (Generic): ['PALBOCICLIB', 'RIBOCICLIB', 'ABEMACICLIB']\n",
      "Overlap: True\n",
      "====================================\n",
      "Index: 23\n",
      "Title T0: comparative study on the efficacy and exposure of molecular target agents in nonsmall cell lung cancer pdx models with driver genetic alterations\n",
      "Title T1: comparative study on the efficacy and exposure of molecular target agents in non small cell lung cancer pdx models with driver genetic alterations\n",
      "Drug T0 (Generic): ['AFATINIB', 'BRIGATINIB', 'CRIZOTINIB', 'ENTRECTINIB', 'GEFITINIB', 'LORLATINIB', 'OSIMERTINIB']\n",
      "Drug T1 (Generic): ['GEFITINIB', 'OSIMERTINIB', 'AFATINIB', 'CRIZOTINIB', 'ENTRECTINIB', 'BRIGATINIB', 'LORLATINIB', 'POZIOTINIB', 'TRASTUZUMAB DERUXTECAN']\n",
      "Overlap: True\n",
      "====================================\n",
      "Index: 24\n",
      "Title T0: the lifted veil of uncommon egfr mutation pl747p in non small cell lung cancer molecular feature and targeting sensitivity to tyrosine kinase inhibitors\n",
      "Title T1: the lifted veil of uncommon egfr mutation pl747p in non small cell lung cancer molecular feature and targeting sensitivity to tyrosine kinase inhibitors\n",
      "Drug T0 (Generic): ['AFATINIB', 'DACOMITINIB', 'OSIMERTINIB']\n",
      "Drug T1 (Generic): ['ERLOTINIB', 'GEFITINIB', 'OSIMERTINIB', 'AFATINIB']\n",
      "Overlap: True\n",
      "====================================\n",
      "Index: 25\n",
      "Title T0: overcoming osimertinib resistance with akt inhibition in egfrm driven nonsmall cell lung cancer with pik3ca pten alterations\n",
      "Title T1: overcoming osimertinib resistance with akt inhibition in egfrm driven nonsmall cell lung cancer with pik3ca pten alterations\n",
      "Drug T0 (Generic): ['CAPIVASERTIB', 'OSIMERTINIB']\n",
      "Drug T1 (Generic): ['OSIMERTINIB', 'CAPIVASERTIB']\n",
      "Overlap: True\n",
      "====================================\n",
      "Index: 26\n",
      "Title T0: evaluation of combined chemotherapy and genomic driven targeted therapy in patient derived xenografts identifies new therapeutic approaches in squamous non small cell lung cancer patients\n",
      "Title T1: evaluation of combined chemotherapy and genomic driven targeted therapy in patient derived xenografts identifies new therapeutic approaches in squamous non small cell lung cancer patients\n",
      "Drug T0 (Generic): ['AFATINIB', 'TRAMETINIB']\n",
      "Drug T1 (Generic): ['SORAFENIB', 'GEMCITABINE', 'CISPLATIN', 'BEVACIZUMAB']\n",
      "Overlap: False\n",
      "====================================\n",
      "Index: 27\n",
      "Title T0: exploration of immune modulatory effects of amivantamab in combination with pembrolizumab in lung and head and neck squamous cell carcinoma\n",
      "Title T1: exploration of immune modulatory effects of amivantamab in combination with pembrolizumab in lung and head and neck squamous cell carcinoma\n",
      "Drug T0 (Generic): ['PEMBROLIZUMAB', 'AMIVANTAMAB']\n",
      "Drug T1 (Generic): ['AMIVANTAMAB', 'PEMBROLIZUMAB']\n",
      "Overlap: True\n",
      "====================================\n",
      "Index: 28\n",
      "Title T0: krt 232 and navitoclax enhance trametinib anti cancer activity in non small cell lung cancer patient derived xenografts with kras mutations\n",
      "Title T1: krt 232 and navitoclax enhance trametinibs anti cancer activity in non small cell lung cancer patient derived xenografts with kras mutations\n",
      "Drug T0 (Generic): ['NAVTEMADLIN', 'krt232', 'NAVITOCLAX', 'TRAMETINIB']\n",
      "Drug T1 (Generic): ['TRAMETINIB', 'NAVITOCLAX', 'NAVTEMADLIN']\n",
      "Overlap: True\n",
      "\n",
      "====================================\n",
      "Drug Recall (drug ÍµêÏßëÌï© 1Í∞ú Ïù¥ÏÉÅ Í∏∞Ï§Ä): 0.8276\n",
      "Matched Titles: 29 / 163\n"
     ]
    }
   ],
   "source": [
    "# ======================================\n",
    "# 0Ô∏è‚É£ ÌåêÎã§Ïä§ Ï∂úÎ†• ÏòµÏÖò: Ï†ÑÏ≤¥ ÌôïÏù∏ Í∞ÄÎä•\n",
    "# ======================================\n",
    "import pandas as pd\n",
    "\n",
    "pd.set_option('display.max_rows', None)       # Î™®Îì† Ìñâ Ï∂úÎ†•\n",
    "pd.set_option('display.max_columns', None)    # Î™®Îì† Ïó¥ Ï∂úÎ†•\n",
    "pd.set_option('display.max_colwidth', None)   # Ïó¥ ÎÇ¥Ïö© Í∏∏Ïù¥ Ï†úÌïú ÏóÜÏùå\n",
    "\n",
    "# ======================================\n",
    "# 1Ô∏è‚É£ Drug Generic Î≥ÄÌôò\n",
    "# ======================================\n",
    "from drugname_standardizer import DrugStandardizer\n",
    "\n",
    "ds = DrugStandardizer()\n",
    "\n",
    "def convert_to_generic(drug_list):\n",
    "    # ; Íµ¨Î∂ÑÏûêÎ°ú ÎêòÏñ¥ ÏûàÎã§Î©¥ Î¶¨Ïä§Ìä∏Î°ú Î≥ÄÌôò ÌõÑ generic Î≥ÄÌôò\n",
    "    return [ds.standardize_name(d) for d in drug_list]\n",
    "\n",
    "# t0, t1 drug_list Ïª¨Îüº Ï°¥Ïû¨ Í∞ÄÏ†ï\n",
    "t0[\"drug_list\"] = t0[\"drug_list\"].apply(convert_to_generic)\n",
    "t1[\"drug_list\"] = t1[\"drug_list\"].apply(convert_to_generic)\n",
    "\n",
    "# ======================================\n",
    "# 2Ô∏è‚É£ Drug Overlap Í≥ÑÏÇ∞ + ÌñâÎ≥Ñ ÌîÑÎ¶∞Ìä∏\n",
    "# ======================================\n",
    "overlap_list = []\n",
    "\n",
    "for idx, row in matched_df.iterrows():\n",
    "    # t0, t1 drug Î¶¨Ïä§Ìä∏ Í∞ÄÏ†∏Ïò§Í∏∞\n",
    "    row_t0_drugs = row[\"drug_t0\"]\n",
    "    row_t1_drugs = row[\"drug_t1\"]\n",
    "    \n",
    "    # ÍµêÏßëÌï© Ï°¥Ïû¨ Ïó¨Î∂Ä ÌôïÏù∏\n",
    "    overlap = any(d in row_t1_drugs for d in row_t0_drugs)\n",
    "    overlap_list.append(overlap)\n",
    "    \n",
    "    # ÌñâÎ≥Ñ Ï∂úÎ†•\n",
    "    print(\"====================================\")\n",
    "    print(f\"Index: {idx}\")\n",
    "    print(f\"Title T0: {row['title_t0']}\")\n",
    "    print(f\"Title T1: {row['title_t1']}\")\n",
    "    print(f\"Drug T0 (Generic): {row_t0_drugs}\")\n",
    "    print(f\"Drug T1 (Generic): {row_t1_drugs}\")\n",
    "    print(f\"Overlap: {overlap}\")\n",
    "\n",
    "matched_df[\"drug_overlap\"] = overlap_list\n",
    "\n",
    "# ======================================\n",
    "# 3Ô∏è‚É£ Drug Recall Í≥ÑÏÇ∞\n",
    "# ======================================\n",
    "true_positives = matched_df[\"drug_overlap\"].sum()\n",
    "drug_recall = true_positives / len(matched_df) if len(matched_df) > 0 else 0\n",
    "\n",
    "print(\"\\n====================================\")\n",
    "print(f\"Drug Recall (drug ÍµêÏßëÌï© 1Í∞ú Ïù¥ÏÉÅ Í∏∞Ï§Ä): {drug_recall:.4f}\")\n",
    "print(f\"Matched Titles: {len(matched_df)} / {len(t0)}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "d9cc2fb4",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python (rag_env)",
   "language": "python",
   "name": "rag_env"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.18"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
